HASPIN
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
T Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: T Sites / T Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| O15371 | T49 | Sugiyama | EIF3D EIF3S7 | PyQPFsKGDRLGKVADWtGAtyQDKRYTNKYSSQFGGGSQY |
| O43390 | T137 | Sugiyama | HNRNPR HNRPR | ESTKGPDEAKIKALLERtGytLDVttGQRKYGGPPPDSVYS |
| O60506 | T134 | Sugiyama | SYNCRIP HNRPQ NSAP1 | DSSKGPDEAKIKALLERtGytLDVttGQRKYGGPPPDSVYS |
| O60841 | S186 | Sugiyama | EIF5B IF2 KIAA0741 | EDEDNsKKIKERsRINssGEsGDEsDEFLQsRKGQKKNQKN |
| O95218 | S181 | Sugiyama | ZRANB2 ZIS ZNF265 | DEDLsKyKLDEDEDEDDADLsKyNLDAsEEEDsNKKKSNRR |
| P00558 | T168 | Sugiyama | PGK1 PGKA MIG10 OK/SW-cl.110 | EAFRAsLSKLGDVyVNDAFGtAHRAHssMVGVNLPQKAGGF |
| P02545 | S583 | Sugiyama | LMNA LMN1 | HHHHGsHCsssGDPAEYNLRsRtVLCGtCGQPADKAsAsGs |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P07205 | T168 | Sugiyama | PGK2 PGKB | EAFRAsLSKLGDVyVNDAFGtAHRAHSSMVGVNLPHKASGF |
| P10412 | S55 | Sugiyama | H1-4 H1F4 HIST1H1E | AsGPPVsELItKAVAASKERsGVsLAALKKALAAAGyDVEK |
| P13639 | S593 | Sugiyama | EEF2 EF2 | SDPVVsyREtVsEEsNVLCLsKsPNKHNRLyMKARPFPDGL |
| P15880 | T202 | Sugiyama | RPS2 RPS4 | CKVTGRCGsVLVRLIPAPRGtGIVsAPVPKKLLMMAGIDDC |
| P15880 | T232 | Sugiyama | RPS2 RPS4 | KLLMMAGIDDCytsARGCtAtLGNFAKATFDAISKTysyLt |
| P15880 | T278 | Sugiyama | RPS2 RPS4 | EtVFtKsPyQEFtDHLVKtHtRVsVQRtQAPAVATt_____ |
| P15880 | T285 | Sugiyama | RPS2 RPS4 | PyQEFtDHLVKtHtRVsVQRtQAPAVATt____________ |
| P16402 | S56 | Sugiyama | H1-3 H1F3 HIST1H1D | AsGPPVsELItKAVAASKERsGVsLAALKKALAAAGyDVEK |
| P16403 | S55 | Sugiyama | H1-2 H1F2 HIST1H1C | AsGPPVsELItKAVAASKERsGVsLAALKKALAAAGyDVEK |
| P17812 | S574 | Sugiyama | CTPS1 CTPS | YLQKGCRLsPRDtysDRsGsssPDsEItELKFPsINHD___ |
| P18077 | Y14 | Sugiyama | RPL35A GIG33 | _______MSGRLWSKAIFAGyKRGLRNQREHTALLKIEGVy |
| P18124 | T17 | Sugiyama | RPL7 | ____MEGVEEKKKEVPAVPEtLKKKRRNFAELKIKRLRKKF |
| P18583 | S2011 | Sugiyama | SON C21orf50 DBP5 KIAA1019 NREBP HSPC310 HSPC312 | RSRTPSRRRRSRSVVRRRsFsIsPVRLRRSRTPLRRRFsRs |
| P18621 | S5 | Sugiyama | RPL17 | ________________MVRysLDPENPtKsCKSRGSNLRVH |
| P19338 | S458 | Sugiyama | NCL | TEADAEKTFEEKQGtEIDGRsIsLyytGEKGQNQDYRGGKN |
| P20618 | S157 | Sugiyama | PSMB1 PSC5 | IIGGLDEEGKGAVysFDPVGsyQRDsFKAGGSASAMLQPLL |
| P22090 | S204 | Sugiyama | RPS4Y1 RPS4Y PRO2646 | IGGANLGRVGVITNRERHPGsFDVVHVKDANGNSFATRLSN |
| P22626 | S351 | Sugiyama | HNRNPA2B1 HNRPA2B1 | yGGGNyGPGGsGGsGGyGGRsRy__________________ |
| P22626 | Y347 | Sugiyama | HNRNPA2B1 HNRPA2B1 | MGGPyGGGNyGPGGsGGsGGyGGRsRy______________ |
| P26373 | S77 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | PIVRCPTVRYHTKVRAGRGFsLEELRVAGIHKKVARTIGIs |
| P35268 | T62 | Sugiyama | RPL22 | FLQERIKVNGKAGNLGGGVVtIERsKSKITVTSEVPFSKRY |
| P36578 | S87 | Sugiyama | RPL4 RPL1 | WGtGRAVARIPRVRGGGtHRsGQGAFGNMCRGGRMFAPTKT |
| P36578 | T69 | Sugiyama | RPL4 RPL1 | RQPyAVsELAGHQtsAEsWGtGRAVARIPRVRGGGtHRsGQ |
| P36578 | T84 | Sugiyama | RPL4 RPL1 | AEsWGtGRAVARIPRVRGGGtHRsGQGAFGNMCRGGRMFAP |
| P37108 | T45 | Sugiyama | SRP14 | sVyItLKKYDGRTKPIPKKGtVEGFEPADNKCLLRATDGKK |
| P38646 | T120 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | LVGMPAKRQAVtNPNNtFyAtKRLIGRRYDDPEVQKDIKNV |
| P38646 | T86 | Sugiyama | HSPA9 GRP75 HSPA9B mt-HSP70 | CVAVMEGKQAKVLENAEGARttPsVVAFtADGERLVGMPAK |
| P39023 | S13 | Sugiyama | RPL3 OK/SW-cl.32 | ________MSHRKFSAPRHGsLGFLPRKRSSRHRGKVKSFP |
| P42677 | S78 | Sugiyama | RPS27 MPS1 | GCSTVLCQPTGGKARLtEGCsFRRKQH______________ |
| P46778 | T124 | Sugiyama | RPL21 | sFLKRVKENDQKKKEAKEKGtWVQLKRQPAPPREAHFVRTN |
| P46778 | T29 | Sugiyama | RPL21 | RGTRYMFSRPFRKHGVVPLAtyMRIYKKGDIVDIKGMGTVQ |
| P46779 | T81 | Sugiyama | RPL28 | VVVIKRRSGQRKPAtsyVRttINKNARAtLsSIRHMIRKNK |
| P46783 | T148 | Sugiyama | RPS10 | RRSAVPPGADKKAEAGAGsAtEFQFRGGFGRGRGQPPQ___ |
| P47914 | T151 | Sugiyama | RPL29 | DQTKAQAAAPAsVPAQAPKRtQAPtKAsE____________ |
| P47914 | T155 | Sugiyama | RPL29 | AQAAAPAsVPAQAPKRtQAPtKAsE________________ |
| P50914 | T43 | Sugiyama | RPL14 | KLVAIVDVIDQNRALVDGPCtQVRRQAMPFKCMQLTDFILK |
| P60709 | S323 | Sugiyama | ACTB | ttMyPGIADRMQKEItALAPstMKIKIIAPPERKYsVWIGG |
| P60709 | T324 | Sugiyama | ACTB | tMyPGIADRMQKEItALAPstMKIKIIAPPERKYsVWIGGs |
| P61313 | S97 | Sugiyama | RPL15 EC45 TCBAP0781 | KGAtyGKPVHHGVNQLKFARsLQsVAEERAGRHCGALRVLN |
| P61313 | Y6 | Sugiyama | RPL15 EC45 TCBAP0781 | _______________MGAYKyIQELWRKKQSDVMRFLLRVR |
| P61353 | S39 | Sugiyama | RPL27 | SGRKAVIVKNIDDGtsDRPysHALVAGIDRyPRKVTAAMGK |
| P61513 | T16 | Sugiyama | RPL37A | _____MAKRTKKVGIVGKyGtRYGAsLRKMVKKIEISQHAK |
| P62081 | T121 | Sugiyama | RPS7 | LPKPTRKSRTKNKQKRPRsRtLtAVHDAILEDLVFPsEIVG |
| P62081 | T123 | Sugiyama | RPS7 | KPTRKSRTKNKQKRPRsRtLtAVHDAILEDLVFPsEIVGKR |
| P62249 | S9 | Sugiyama | RPS16 | ____________MPsKGPLQsVQVFGRKKTATAVAHCKRGN |
| P62263 | S139 | Sugiyama | RPS14 PRO2640 | LARSGMKIGRIEDVtPIPsDstRRKGGRRGRRL________ |
| P62263 | T140 | Sugiyama | RPS14 PRO2640 | ARSGMKIGRIEDVtPIPsDstRRKGGRRGRRL_________ |
| P62273 | Y7 | Sugiyama | RPS29 | ______________MGHQQLyWsHPRKFGQGSRSCRVCSNR |
| P62277 | S12 | Sugiyama | RPS13 | _________MGRMHAPGKGLsQsALPyRRsVPtWLKLTsDD |
| P62277 | S14 | Sugiyama | RPS13 | _______MGRMHAPGKGLsQsALPyRRsVPtWLKLTsDDVK |
| P62280 | T15 | Sugiyama | RPS11 | ______MADIQTERAyQKQPtIFQNKKRVLLGEtGKEKLPR |
| P62701 | S204 | Sugiyama | RPS4X CCG2 RPS4 SCAR | tGGANLGRIGVITNRERHPGsFDVVHVKDANGNSFATRLsN |
| P62736 | S325 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | tTMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGG |
| P62736 | T326 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | TMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGGS |
| P62750 | T42 | Sugiyama | RPL23A | LKAKKAVLKGVHSHKKKKIRtsPTFRRPKTLRLRRQPKYPR |
| P62899 | S15 | Sugiyama | RPL31 | ______MAPAKKGGEKKKGRsAINEVVtREytINIHKRIHG |
| P62899 | T26 | Sugiyama | RPL31 | KGGEKKKGRsAINEVVtREytINIHKRIHGVGFKKRAPRAL |
| P62910 | S105 | Sugiyama | RPL32 PP9932 | LEVLLMCNKsyCAEIAHNVSsKNRKAIVERAAQLAIRVTNP |
| P62917 | S14 | Sugiyama | RPL8 | _______MGRVIRGQRKGAGsVFRAHVKHRKGAARLRAVDF |
| P62917 | T135 | Sugiyama | RPL8 | CLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKLPSGSK |
| P62917 | T143 | Sugiyama | RPL8 | RGKLARAsGNyAtVIsHNPEtKKtRVKLPSGSKKVISSANR |
| P62917 | T146 | Sugiyama | RPL8 | LARAsGNyAtVIsHNPEtKKtRVKLPSGSKKVISSANRAVV |
| P63261 | S323 | Sugiyama | ACTG1 ACTG | ttMyPGIADRMQKEItALAPstMKIKIIAPPERKYsVWIGG |
| P63261 | T324 | Sugiyama | ACTG1 ACTG | tMyPGIADRMQKEItALAPstMKIKIIAPPERKYsVWIGGs |
| P63267 | S324 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | tTMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGG |
| P63267 | T325 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | TMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGGS |
| P67809 | S136 | Sugiyama | YBX1 NSEP1 YB1 | GEKGAEAANVtGPGGVPVQGsKYAADRNHYRRYPRRRGPPR |
| P67809 | Y196 | Sugiyama | YBX1 NSEP1 YB1 | sAPEGQAQQRRPyRRRRFPPyyMRRPYGRRPQysNPPVQGE |
| P68032 | S325 | Sugiyama | ACTC1 ACTC | tTMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGG |
| P68032 | T326 | Sugiyama | ACTC1 ACTC | TMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGGS |
| P68133 | S325 | Sugiyama | ACTA1 ACTA | TTMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGG |
| P68133 | T326 | Sugiyama | ACTA1 ACTA | TMYPGIADRMQKEItALAPstMKIKIIAPPERKYSVWIGGS |
| P68431 | T4 | GPS6|SIGNOR|EPSD | H3C1 H3FA HIST1H3A; H3C2 H3FL HIST1H3B; H3C3 H3FC HIST1H3C; H3C4 H3FB HIST1H3D; H3C6 H3FD HIST1H3E; H3C7 H3FI HIST1H3F; H3C8 H3FH HIST1H3G; H3C10 H3FK HIST1H3H; H3C11 H3FF HIST1H3I; H3C12 H3FJ HIST1H3J | _________________MARtKQtARKstGGKAPRKQLATK |
| P83731 | T52 | Sugiyama | RPL24 | LNAKCEsAFLSKRNPRQINWtVLyRRKHKKGQsEEIQKKRT |
| P83731 | Y55 | Sugiyama | RPL24 | KCEsAFLSKRNPRQINWtVLyRRKHKKGQsEEIQKKRTRRA |
| P84098 | S37 | Sugiyama | RPL19 | CGKKKVWLDPNEtNEIANANsRQQIRKLIKDGLIIRKPVtV |
| P84243 | T4 | GPS6|EPSD | H3-3A H3.3A H3F3 H3F3A PP781; H3-3B H3.3B H3F3B | _________________MARtKQTARKstGGKAPRKQLATK |
| Q00059 | S160 | Sugiyama | TFAM TCF6 TCF6L2 | RKAMTKKKELTLLGKPKRPRsAYNVyVAERFQEAKGDsPQE |
| Q01105 | S168 | Sugiyama | SET | ENKVLSKEFHLNEsGDPssKstEIKWKSGKDLTKRssQTQN |
| Q02543 | S123 | Sugiyama | RPL18A | AGAVtQCyRDMGARHRARAHsIQIMKVEEIAASKCRRPAVK |
| Q04695 | T410 | Sugiyama | KRT17 | GEDAHLTQyKKEPVTTRQVRtIVEEVQDGKVISSREQVHQT |
| Q07020 | T136 | Sugiyama | RPL18 | AGGKILtFDQLALDsPKGCGtVLLsGPRKGREVYRHFGKAP |
| Q07020 | T85 | Sugiyama | RPL18 | RMIRKMKLPGRENKtAVVVGtItDDVRVQEVPKLKVCALRV |
| Q13263 | S471 | Sugiyama | TRIM28 KAP1 RNF96 TIF1B | FGsGDDPyssAEPHVsGVKRsRsGEGEVsGLMRKVPRVsLE |
| Q13442 | S63 | Sugiyama | PDAP1 HASPP28 | GGDGAAGDPKKEKKsLDsDEsEDEEDDyQQKRKGVEGLIDI |
| Q16181 | T426 | Sugiyama | SEPTIN7 CDC10 SEPT7 | DEKANWEAQQRILEQQNssRtLEKNKKKGKIF_________ |
| Q16695 | T4 | GPS6 | H3-4 H3FT HIST3H3 | _________________MARtKQTARKsTGGKAPRKQLATK |
| Q71DI3 | T4 | GPS6|EPSD | H3C15 HIST2H3A; H3C14 H3F2 H3FM HIST2H3C; H3C13 HIST2H3D | _________________MARtKQTARKsTGGKAPRKQLATK |
| Q71UM5 | S78 | Sugiyama | RPS27L | GCSTVLCQPTGGKARLtEGCsFRRKQH______________ |
| Q86V81 | S145 | Sugiyama | ALYREF ALY BEF THOC4 | LFAEFGtLKKAAVHYDRsGRsLGtADVHFERKADALKAMKQ |
| Q8TF76 | S108 | Sugiyama | HASPIN GSG2 | PKDRPsLTVtPKRWKLRARPsLtVtPRRLGLRARPPQKCSt |
| Q8TF76 | S147 | Sugiyama | HASPIN GSG2 | StPCGPLRLPPFPsRDsGRLsPDLsVCGQPRDGDELGIsAS |
| Q8TF76 | S151 | Sugiyama | HASPIN GSG2 | GPLRLPPFPsRDsGRLsPDLsVCGQPRDGDELGIsASLFSS |
| Q8TF76 | S288 | Sugiyama | HASPIN GSG2 | EsCCKRKLVVGNGPEGPGLsstGKRRAtGQDSCQERGLQEA |
| Q8TF76 | S349 | Sugiyama | HASPIN GSG2 | DRLERTRSSRKSKHQEATEtsLLHsHRFKKGQKLGKDsFPT |
| Q8TF76 | S353 | Sugiyama | HASPIN GSG2 | RTRSSRKSKHQEATEtsLLHsHRFKKGQKLGKDsFPTQDLt |
| Q8TF76 | S389 | Sugiyama | HASPIN GSG2 | TQDLtPLQNVCFWTKTRAsFsFHKKKIVTDVSEVCSIYTTA |
| Q8TF76 | S543 | Sugiyama | HASPIN GSG2 | GSHQKTFEEILPEIIISKELsLLSGEVCNRTEGFIGLNSVH |
| Q8TF76 | T128 | Sugiyama | HASPIN GSG2 | sLtVtPRRLGLRARPPQKCStPCGPLRLPPFPsRDsGRLsP |
| Q8TF76 | T15 | Sugiyama | HASPIN GSG2 | ______MAAsLPGPGsRLFRtyGAADGRRQRRPGREAAQWF |
| Q8TF76 | T289 | Sugiyama | HASPIN GSG2 | sCCKRKLVVGNGPEGPGLsstGKRRAtGQDSCQERGLQEAV |
| Q8TF76 | Y16 | Sugiyama | HASPIN GSG2 | _____MAAsLPGPGsRLFRtyGAADGRRQRRPGREAAQWFP |
| Q92522 | T55 | Sugiyama | H1-10 H1FX | KRKNSKKKNQPGKySQLVVEtIRRLGERNGSSLAKIYTEAK |
| Q92882 | T200 | Sugiyama | OSTF1 | ATNAACAsLLKKKQGTDAVRtLsNAEDyLDDEDsD______ |
| Q99543 | T268 | Sugiyama | DNAJC2 MPHOSPH11 MPP11 ZRF1 | EKQNRATRAQRKKEEMNRIRtLVDNAysCDPRIKKFKEEEK |
| Q99613 | T880 | Sugiyama | EIF3C EIF3S8 | AEKLGsLVENNERVFDHKQGtyGGyFRDQKDGYRKNEGYMR |
| Q9BQ69 | T196 | Sugiyama | MACROD1 LRP16 | SLLGGGGVDGCIHRAAGPLLtDECRtLQSCKTGKAKITGGY |
| Q9BQ69 | T201 | Sugiyama | MACROD1 LRP16 | GGVDGCIHRAAGPLLtDECRtLQSCKTGKAKITGGYRLPAK |
| Q9H0H5 | S206 | Sugiyama | RACGAP1 KIAA1478 MGCRACGAP | tsRQFVDGPPGPVKKtRsIGsAVDQGNEsIVAKTTVTVPND |
| Q9H0H5 | T251 | Sugiyama | RACGAP1 KIAA1478 MGCRACGAP | EAVSTIETVPYWtRSRRKtGtLQPWNsDstLNSRQLEPRTE |
| Q9NQ39 | T159 | Sugiyama | RPS10P5 RPS10L | RRCSVPPGADKKAEAGAGsAtEFQFRGRCGRGRGQPPQ___ |
| Q9NZB2 | T991 | Sugiyama | FAM120A C9orf10 KIAA0183 OSSA | PLQVVSVGGPARGRPRGVIstPVIRTFGRGGRYYGRGYKNQ |
| Q9P258 | T521 | Sugiyama | RCC2 KIAA1470 TD60 | RDESETEKEKIKKLPEYNPRtL___________________ |
| Q9UGV2 | S327 | Sugiyama | NDRG3 | KYFLQGMGYIPSASMTRLARsRtHstsssLGsGEsPFsRsV |
| Q9UGV2 | T329 | Sugiyama | NDRG3 | FLQGMGYIPSASMTRLARsRtHstsssLGsGEsPFsRsVts |
| Q9UQ35 | S1541 | Sugiyama | SRRM2 KIAA0324 SRL300 SRM300 HSPC075 | ssVDQKtVARtPLGQRsRsGssQELDVKPsAsPQERsEsDs |
| Q9UQ35 | S2102 | Sugiyama | SRRM2 KIAA0324 SRL300 SRM300 HSPC075 | GSSSDRSRsAtPPATRNHsGsRtPPVALNsSRMsCFsRPsM |
| Q9Y2V2 | T50 | Sugiyama | CARHSP1 | sPsPLRGNVVPsPLPtRRtRtFsAtVRASQGPVYKGVCKCF |
| Q9Y2X3 | S440 | Sugiyama | NOP58 NOL5 NOP5 HSPC120 | EHKSEVKtyDPSGDstLPtCsKKRKIEQVDKEDEITEKKAK |
| Q9Y388 | S227 | Sugiyama | RBMX2 CGI-79 | SKNSERAQKSEPREGQKLPKsRTAYsGGAEDLERELKKEKP |
| Q9Y3U8 | Y53 | Sugiyama | RPL36 | LTKHTKFVRDMIREVCGFAPyERRAMELLKVSKDKRALKFI |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.190327e-09 | 8.924 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 1.142242e-09 | 8.942 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 2.104844e-09 | 8.677 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 1.749517e-09 | 8.757 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 2.388514e-09 | 8.622 | 0 | 0 |
| M Phase | R-HSA-68886 | 2.855665e-08 | 7.544 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 2.603845e-08 | 7.584 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 3.622829e-08 | 7.441 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 2.294046e-07 | 6.639 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 2.294046e-07 | 6.639 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 2.433944e-07 | 6.614 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 2.230503e-07 | 6.652 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 5.763339e-07 | 6.239 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 2.351650e-06 | 5.629 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 2.712458e-06 | 5.567 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 3.356275e-06 | 5.474 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 7.470189e-06 | 5.127 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 1.526471e-05 | 4.816 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 2.437127e-05 | 4.613 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 2.738986e-05 | 4.562 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 3.580009e-05 | 4.446 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 3.894182e-05 | 4.410 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 3.879383e-05 | 4.411 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 4.483870e-05 | 4.348 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 5.478049e-05 | 4.261 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 6.391151e-05 | 4.194 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 7.309837e-05 | 4.136 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 7.574023e-05 | 4.121 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 7.495848e-05 | 4.125 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 1.218149e-04 | 3.914 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 1.330433e-04 | 3.876 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 1.391088e-04 | 3.857 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 1.435875e-04 | 3.843 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 1.458446e-04 | 3.836 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 1.805185e-04 | 3.743 | 0 | 0 |
| Kinesins | R-HSA-983189 | 2.140624e-04 | 3.669 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 2.368467e-04 | 3.626 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 2.420215e-04 | 3.616 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 2.514934e-04 | 3.599 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 2.514934e-04 | 3.599 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 2.874307e-04 | 3.541 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 3.091863e-04 | 3.510 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 3.248328e-04 | 3.488 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 3.198911e-04 | 3.495 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 3.555262e-04 | 3.449 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 3.913290e-04 | 3.407 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 4.244091e-04 | 3.372 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 4.244091e-04 | 3.372 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 4.413905e-04 | 3.355 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 4.244091e-04 | 3.372 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 5.330859e-04 | 3.273 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 5.347134e-04 | 3.272 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 5.995981e-04 | 3.222 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 6.043285e-04 | 3.219 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 6.358635e-04 | 3.197 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 6.996085e-04 | 3.155 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 6.996085e-04 | 3.155 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 7.352629e-04 | 3.134 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 8.211918e-04 | 3.086 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 8.928145e-04 | 3.049 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 9.821458e-04 | 3.008 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 1.002743e-03 | 2.999 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 1.002743e-03 | 2.999 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 1.048765e-03 | 2.979 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 1.048765e-03 | 2.979 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 1.043411e-03 | 2.982 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 1.099351e-03 | 2.959 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 1.566449e-03 | 2.805 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 1.641767e-03 | 2.785 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 1.647811e-03 | 2.783 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 1.752495e-03 | 2.756 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 1.898192e-03 | 2.722 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 1.866562e-03 | 2.729 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 1.931803e-03 | 2.714 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 2.053021e-03 | 2.688 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 2.053021e-03 | 2.688 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 2.055270e-03 | 2.687 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 2.291186e-03 | 2.640 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 2.419017e-03 | 2.616 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 2.484258e-03 | 2.605 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 2.537478e-03 | 2.596 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 2.583779e-03 | 2.588 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 2.817127e-03 | 2.550 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 2.825440e-03 | 2.549 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 2.885048e-03 | 2.540 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 2.960568e-03 | 2.529 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 2.979853e-03 | 2.526 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 3.020432e-03 | 2.520 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 3.301183e-03 | 2.481 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 3.267763e-03 | 2.486 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 3.369815e-03 | 2.472 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 3.444927e-03 | 2.463 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 3.444927e-03 | 2.463 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 3.444927e-03 | 2.463 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 3.444927e-03 | 2.463 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 3.444927e-03 | 2.463 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 3.576270e-03 | 2.447 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 3.988519e-03 | 2.399 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 3.988519e-03 | 2.399 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 4.066752e-03 | 2.391 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 4.066752e-03 | 2.391 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 4.207978e-03 | 2.376 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 4.153711e-03 | 2.382 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 4.337918e-03 | 2.363 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 4.360092e-03 | 2.361 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 4.259069e-03 | 2.371 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 4.504615e-03 | 2.346 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 4.758110e-03 | 2.323 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 4.948786e-03 | 2.306 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 4.958749e-03 | 2.305 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 4.958749e-03 | 2.305 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 5.263630e-03 | 2.279 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 5.269410e-03 | 2.278 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 5.642427e-03 | 2.249 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 5.642427e-03 | 2.249 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 5.642427e-03 | 2.249 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 6.260424e-03 | 2.203 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 6.392493e-03 | 2.194 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 6.546406e-03 | 2.184 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 6.546406e-03 | 2.184 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 6.989766e-03 | 2.156 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 7.079503e-03 | 2.150 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 7.099302e-03 | 2.149 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 7.212470e-03 | 2.142 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 7.212470e-03 | 2.142 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 7.899281e-03 | 2.102 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 7.634485e-03 | 2.117 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 7.244022e-03 | 2.140 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 7.212470e-03 | 2.142 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 8.105855e-03 | 2.091 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 8.131713e-03 | 2.090 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 8.131713e-03 | 2.090 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 8.310119e-03 | 2.080 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 8.310119e-03 | 2.080 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 8.727229e-03 | 2.059 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 9.045311e-03 | 2.044 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 9.076102e-03 | 2.042 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 9.076102e-03 | 2.042 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 9.438774e-03 | 2.025 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 9.487554e-03 | 2.023 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 9.487554e-03 | 2.023 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 1.012662e-02 | 1.995 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 1.012662e-02 | 1.995 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 1.012662e-02 | 1.995 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 1.026888e-02 | 1.988 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 1.047095e-02 | 1.980 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 1.076776e-02 | 1.968 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 1.126766e-02 | 1.948 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 1.126766e-02 | 1.948 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 1.302667e-02 | 1.885 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 1.302667e-02 | 1.885 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 1.302667e-02 | 1.885 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 1.302667e-02 | 1.885 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 1.302667e-02 | 1.885 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 1.302667e-02 | 1.885 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 1.302667e-02 | 1.885 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 1.302667e-02 | 1.885 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 1.302667e-02 | 1.885 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 1.302667e-02 | 1.885 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 1.302667e-02 | 1.885 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 1.302667e-02 | 1.885 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 1.302667e-02 | 1.885 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 1.271961e-02 | 1.896 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 1.217733e-02 | 1.914 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 1.248173e-02 | 1.904 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 1.244675e-02 | 1.905 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 1.258211e-02 | 1.900 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 1.276486e-02 | 1.894 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 1.325475e-02 | 1.878 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 1.325475e-02 | 1.878 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 1.350033e-02 | 1.870 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 1.373613e-02 | 1.862 | 0 | 0 |
| Protein folding | R-HSA-391251 | 1.373613e-02 | 1.862 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 1.379277e-02 | 1.860 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 1.384538e-02 | 1.859 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 1.494692e-02 | 1.825 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 1.532524e-02 | 1.815 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 1.577607e-02 | 1.802 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 1.577607e-02 | 1.802 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 1.669728e-02 | 1.777 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 1.669728e-02 | 1.777 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 1.823189e-02 | 1.739 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 1.888925e-02 | 1.724 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 1.888925e-02 | 1.724 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 1.999769e-02 | 1.699 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 1.888925e-02 | 1.724 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 2.003824e-02 | 1.698 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 1.829661e-02 | 1.738 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 2.049031e-02 | 1.688 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 2.268665e-02 | 1.644 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 2.363622e-02 | 1.626 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 2.371551e-02 | 1.625 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 2.371551e-02 | 1.625 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 2.416225e-02 | 1.617 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 2.428500e-02 | 1.615 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 2.491716e-02 | 1.604 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 2.491716e-02 | 1.604 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 2.573710e-02 | 1.589 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 2.629839e-02 | 1.580 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 2.629839e-02 | 1.580 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 2.643564e-02 | 1.578 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 2.648162e-02 | 1.577 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 2.652755e-02 | 1.576 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 2.771954e-02 | 1.557 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 2.771954e-02 | 1.557 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 2.727692e-02 | 1.564 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 2.975669e-02 | 1.526 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 3.011668e-02 | 1.521 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 2.676420e-02 | 1.572 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 2.676420e-02 | 1.572 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 3.184014e-02 | 1.497 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 2.727692e-02 | 1.564 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 3.209948e-02 | 1.494 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 3.209948e-02 | 1.494 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 3.209948e-02 | 1.494 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 3.209948e-02 | 1.494 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 2.975669e-02 | 1.526 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 2.787014e-02 | 1.555 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 2.787014e-02 | 1.555 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 2.870533e-02 | 1.542 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 2.865934e-02 | 1.543 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 2.778069e-02 | 1.556 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 3.011668e-02 | 1.521 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 3.000713e-02 | 1.523 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 3.018452e-02 | 1.520 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 3.247862e-02 | 1.488 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 3.271733e-02 | 1.485 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 3.331343e-02 | 1.477 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 3.331343e-02 | 1.477 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 3.331343e-02 | 1.477 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 3.331343e-02 | 1.477 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 3.359086e-02 | 1.474 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 3.579989e-02 | 1.446 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 3.619554e-02 | 1.441 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 3.669709e-02 | 1.435 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 3.669709e-02 | 1.435 | 0 | 0 |
| IRS activation | R-HSA-74713 | 3.669709e-02 | 1.435 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 3.669709e-02 | 1.435 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 3.710750e-02 | 1.431 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 3.714182e-02 | 1.430 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 3.733649e-02 | 1.428 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 3.733649e-02 | 1.428 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 3.733649e-02 | 1.428 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 3.755557e-02 | 1.425 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 3.943609e-02 | 1.404 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 4.113980e-02 | 1.386 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 4.113980e-02 | 1.386 | 0 | 0 |
| Deletions in the AXIN1 gene destabilize the destruction complex | R-HSA-5467345 | 4.182638e-02 | 1.379 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 4.182638e-02 | 1.379 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 4.182638e-02 | 1.379 | 0 | 0 |
| Defective translocation of RB1 mutants to the nucleus | R-HSA-9661070 | 4.182638e-02 | 1.379 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 4.205929e-02 | 1.376 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 4.331360e-02 | 1.363 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 4.662432e-02 | 1.331 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 4.902781e-02 | 1.310 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 5.236968e-02 | 1.281 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 4.712931e-02 | 1.327 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 4.902781e-02 | 1.310 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 4.569982e-02 | 1.340 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 4.932730e-02 | 1.307 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 4.675475e-02 | 1.330 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 5.311955e-02 | 1.275 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 5.311955e-02 | 1.275 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 4.521571e-02 | 1.345 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 4.902781e-02 | 1.310 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 4.902781e-02 | 1.310 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 4.932730e-02 | 1.307 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 5.295861e-02 | 1.276 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 5.417579e-02 | 1.266 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 5.447762e-02 | 1.264 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 5.466469e-02 | 1.262 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 5.466469e-02 | 1.262 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 5.466469e-02 | 1.262 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 5.607743e-02 | 1.251 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 5.667012e-02 | 1.247 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 5.740632e-02 | 1.241 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 5.740632e-02 | 1.241 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 5.806432e-02 | 1.236 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 5.916324e-02 | 1.228 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 5.916324e-02 | 1.228 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 5.962542e-02 | 1.225 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 6.228250e-02 | 1.206 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 6.228250e-02 | 1.206 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 6.228250e-02 | 1.206 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 6.274798e-02 | 1.202 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 6.485855e-02 | 1.188 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 6.548488e-02 | 1.184 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 6.645817e-02 | 1.177 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 6.842555e-02 | 1.165 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 6.895445e-02 | 1.161 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 6.895445e-02 | 1.161 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 6.895445e-02 | 1.161 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 6.895445e-02 | 1.161 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 6.946872e-02 | 1.158 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 6.946872e-02 | 1.158 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 6.948739e-02 | 1.158 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 7.029373e-02 | 1.153 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 7.030172e-02 | 1.153 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 7.152694e-02 | 1.146 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 7.471260e-02 | 1.127 | 0 | 0 |
| Defective Mismatch Repair Associated With PMS2 | R-HSA-5632987 | 8.190575e-02 | 1.087 | 0 | 0 |
| Defective Mismatch Repair Associated With MLH1 | R-HSA-5545483 | 8.190575e-02 | 1.087 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 9.310706e-02 | 1.031 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 8.425419e-02 | 1.074 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 8.425419e-02 | 1.074 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 8.425419e-02 | 1.074 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 8.425419e-02 | 1.074 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 8.477550e-02 | 1.072 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 8.829816e-02 | 1.054 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 8.489498e-02 | 1.071 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 9.310706e-02 | 1.031 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 7.701076e-02 | 1.113 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 9.190469e-02 | 1.037 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 8.438123e-02 | 1.074 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 7.701076e-02 | 1.113 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 8.829816e-02 | 1.054 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 7.833975e-02 | 1.106 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 7.629830e-02 | 1.117 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 8.190575e-02 | 1.087 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 8.118596e-02 | 1.091 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 9.402367e-02 | 1.027 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 7.701076e-02 | 1.113 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 8.489498e-02 | 1.071 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 7.833975e-02 | 1.106 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 1.006115e-01 | 0.997 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 8.688209e-02 | 1.061 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 8.688209e-02 | 1.061 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 8.797410e-02 | 1.056 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 8.973905e-02 | 1.047 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 8.797410e-02 | 1.056 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 9.559480e-02 | 1.020 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 9.402367e-02 | 1.027 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 8.797410e-02 | 1.056 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 7.701076e-02 | 1.113 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 8.254922e-02 | 1.083 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 7.547256e-02 | 1.122 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 7.721024e-02 | 1.112 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 1.008305e-01 | 0.996 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 1.016321e-01 | 0.993 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 1.016321e-01 | 0.993 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 1.054277e-01 | 0.977 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 1.071627e-01 | 0.970 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 1.071627e-01 | 0.970 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 1.073956e-01 | 0.969 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 1.073956e-01 | 0.969 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 1.073956e-01 | 0.969 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 1.073956e-01 | 0.969 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 1.073956e-01 | 0.969 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 1.073956e-01 | 0.969 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 1.073956e-01 | 0.969 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 1.073956e-01 | 0.969 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 1.075658e-01 | 0.968 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 1.104549e-01 | 0.957 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 1.104549e-01 | 0.957 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 1.104549e-01 | 0.957 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 1.104549e-01 | 0.957 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 1.104549e-01 | 0.957 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 1.111828e-01 | 0.954 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 1.112469e-01 | 0.954 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 1.144982e-01 | 0.941 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 1.144982e-01 | 0.941 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 1.152841e-01 | 0.938 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 1.170933e-01 | 0.931 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 1.171072e-01 | 0.931 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 1.194658e-01 | 0.923 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 1.195598e-01 | 0.922 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 1.195598e-01 | 0.922 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 1.203110e-01 | 0.920 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 1.203110e-01 | 0.920 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 1.204987e-01 | 0.919 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 1.212349e-01 | 0.916 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 1.212349e-01 | 0.916 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 1.212349e-01 | 0.916 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 1.212349e-01 | 0.916 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 1.212349e-01 | 0.916 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 1.212349e-01 | 0.916 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 1.212349e-01 | 0.916 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 1.212349e-01 | 0.916 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 1.212349e-01 | 0.916 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 1.226404e-01 | 0.911 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 1.230823e-01 | 0.910 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 1.230823e-01 | 0.910 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 1.237272e-01 | 0.908 | 0 | 0 |
| Defective PAPSS2 causes SEMD-PA | R-HSA-3560796 | 1.571119e-01 | 0.804 | 0 | 0 |
| Signaling by RAS GAP mutants | R-HSA-9753510 | 1.571119e-01 | 0.804 | 0 | 0 |
| Mitotic Metaphase/Anaphase Transition | R-HSA-68881 | 1.571119e-01 | 0.804 | 0 | 0 |
| Defective SLC6A5 causes hyperekplexia 3 (HKPX3) | R-HSA-5619089 | 1.571119e-01 | 0.804 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 1.571119e-01 | 0.804 | 0 | 0 |
| TGFBR2 Kinase Domain Mutants in Cancer | R-HSA-3645790 | 1.571119e-01 | 0.804 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of other transcription factors | R-HSA-8866906 | 1.923754e-01 | 0.716 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 1.923754e-01 | 0.716 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 1.923754e-01 | 0.716 | 0 | 0 |
| Defective GCLC causes HAGGSD | R-HSA-5578999 | 1.923754e-01 | 0.716 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 1.923754e-01 | 0.716 | 0 | 0 |
| Classical Kir channels | R-HSA-1296053 | 1.923754e-01 | 0.716 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 2.261657e-01 | 0.646 | 0 | 0 |
| Nucleotide catabolism defects | R-HSA-9735786 | 2.261657e-01 | 0.646 | 0 | 0 |
| Defective PNP disrupts phosphorolysis of (deoxy)guanosine and (deoxy)inosine | R-HSA-9735763 | 2.261657e-01 | 0.646 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 2.261657e-01 | 0.646 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 2.261657e-01 | 0.646 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 2.261657e-01 | 0.646 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 2.261657e-01 | 0.646 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 2.585442e-01 | 0.587 | 0 | 0 |
| Defective SLC1A3 causes episodic ataxia 6 (EA6) | R-HSA-5619062 | 2.585442e-01 | 0.587 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 2.585442e-01 | 0.587 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 1.354790e-01 | 0.868 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 1.500701e-01 | 0.824 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 1.500701e-01 | 0.824 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 1.500701e-01 | 0.824 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 1.500701e-01 | 0.824 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 1.500701e-01 | 0.824 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 1.500701e-01 | 0.824 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 1.500701e-01 | 0.824 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 2.895698e-01 | 0.538 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 2.895698e-01 | 0.538 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 2.895698e-01 | 0.538 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 2.895698e-01 | 0.538 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 2.895698e-01 | 0.538 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 1.800819e-01 | 0.745 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 3.192990e-01 | 0.496 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 3.192990e-01 | 0.496 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 3.192990e-01 | 0.496 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 1.954062e-01 | 0.709 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 1.954062e-01 | 0.709 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 1.385525e-01 | 0.858 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 2.108846e-01 | 0.676 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 2.108846e-01 | 0.676 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 3.477858e-01 | 0.459 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 2.264775e-01 | 0.645 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 2.264775e-01 | 0.645 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 3.750822e-01 | 0.426 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 3.750822e-01 | 0.426 | 0 | 0 |
| RSK activation | R-HSA-444257 | 3.750822e-01 | 0.426 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 3.750822e-01 | 0.426 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 3.750822e-01 | 0.426 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 3.750822e-01 | 0.426 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 3.750822e-01 | 0.426 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 2.578630e-01 | 0.589 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 2.735908e-01 | 0.563 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 2.735908e-01 | 0.563 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 2.893031e-01 | 0.539 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 2.226288e-01 | 0.652 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 3.049738e-01 | 0.516 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 2.450581e-01 | 0.611 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 2.018702e-01 | 0.695 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 3.205788e-01 | 0.494 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 3.360963e-01 | 0.474 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 1.657598e-01 | 0.781 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 3.515063e-01 | 0.454 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 1.415523e-01 | 0.849 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 2.651896e-01 | 0.576 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 1.499515e-01 | 0.824 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 1.499515e-01 | 0.824 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 3.255117e-01 | 0.487 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 3.486578e-01 | 0.458 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 1.499515e-01 | 0.824 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 2.579126e-01 | 0.589 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 2.240413e-01 | 0.650 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 2.115737e-01 | 0.675 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 3.139317e-01 | 0.503 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 2.226288e-01 | 0.652 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 3.076644e-01 | 0.512 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 2.102668e-01 | 0.677 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 3.477858e-01 | 0.459 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 2.509484e-01 | 0.600 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 3.486578e-01 | 0.458 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 1.440733e-01 | 0.841 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 3.449427e-01 | 0.462 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 2.108846e-01 | 0.676 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 1.484082e-01 | 0.829 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 1.792212e-01 | 0.747 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 3.139317e-01 | 0.503 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 1.500701e-01 | 0.824 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | R-HSA-8939242 | 3.750822e-01 | 0.426 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 2.578630e-01 | 0.589 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 2.509484e-01 | 0.600 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 2.509484e-01 | 0.600 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 2.430634e-01 | 0.614 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 3.370905e-01 | 0.472 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 2.386805e-01 | 0.622 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 1.649544e-01 | 0.783 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 2.585442e-01 | 0.587 | 0 | 0 |
| Insulin effects increased synthesis of Xylulose-5-Phosphate | R-HSA-163754 | 3.477858e-01 | 0.459 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 3.750822e-01 | 0.426 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 3.049738e-01 | 0.516 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 2.908113e-01 | 0.536 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 1.312387e-01 | 0.882 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 3.515063e-01 | 0.454 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 1.483967e-01 | 0.829 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 2.261657e-01 | 0.646 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 2.261657e-01 | 0.646 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 2.895698e-01 | 0.538 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 1.385525e-01 | 0.858 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 2.264775e-01 | 0.645 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 1.584822e-01 | 0.800 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 2.421482e-01 | 0.616 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 3.360963e-01 | 0.474 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 1.423359e-01 | 0.847 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 1.500701e-01 | 0.824 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 3.192990e-01 | 0.496 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 1.518950e-01 | 0.818 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 2.006441e-01 | 0.698 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 2.545150e-01 | 0.594 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 3.238982e-01 | 0.490 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 2.226288e-01 | 0.652 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 3.255117e-01 | 0.487 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 2.337950e-01 | 0.631 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 1.484082e-01 | 0.829 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 1.505547e-01 | 0.822 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 2.749658e-01 | 0.561 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 1.898549e-01 | 0.722 | 0 | 0 |
| Loss of Function of TGFBR2 in Cancer | R-HSA-3642278 | 1.571119e-01 | 0.804 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 1.923754e-01 | 0.716 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 2.261657e-01 | 0.646 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 2.261657e-01 | 0.646 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 1.354790e-01 | 0.868 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 2.895698e-01 | 0.538 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 3.192990e-01 | 0.496 | 0 | 0 |
| Intracellular metabolism of fatty acids regulates insulin secretion | R-HSA-434313 | 3.192990e-01 | 0.496 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 2.108846e-01 | 0.676 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 3.477858e-01 | 0.459 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 3.477858e-01 | 0.459 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 2.578630e-01 | 0.589 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 1.898549e-01 | 0.722 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 3.360963e-01 | 0.474 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 3.667906e-01 | 0.436 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 3.667906e-01 | 0.436 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 3.219472e-01 | 0.492 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 2.871245e-01 | 0.542 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 1.279494e-01 | 0.893 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 2.108846e-01 | 0.676 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 3.750822e-01 | 0.426 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 1.780468e-01 | 0.749 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 3.602830e-01 | 0.443 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 1.780468e-01 | 0.749 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 1.484082e-01 | 0.829 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 3.700495e-01 | 0.432 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 3.602830e-01 | 0.443 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 2.464472e-01 | 0.608 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 2.261657e-01 | 0.646 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 1.954062e-01 | 0.709 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 3.477858e-01 | 0.459 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 3.477858e-01 | 0.459 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 2.195102e-01 | 0.659 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 2.375409e-01 | 0.624 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 3.315162e-01 | 0.479 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 1.423359e-01 | 0.847 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 3.637181e-01 | 0.439 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 2.128661e-01 | 0.672 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 2.735908e-01 | 0.563 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 2.912336e-01 | 0.536 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 2.297082e-01 | 0.639 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 1.440733e-01 | 0.841 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 1.440733e-01 | 0.841 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 2.128661e-01 | 0.672 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 2.106376e-01 | 0.676 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 3.486578e-01 | 0.458 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 3.698719e-01 | 0.432 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 2.297082e-01 | 0.639 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 1.923754e-01 | 0.716 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 2.895698e-01 | 0.538 | 0 | 0 |
| Abacavir transmembrane transport | R-HSA-2161517 | 3.192990e-01 | 0.496 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 3.477858e-01 | 0.459 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 2.264775e-01 | 0.645 | 0 | 0 |
| Neurotransmitter uptake and metabolism In glial cells | R-HSA-112313 | 3.750822e-01 | 0.426 | 0 | 0 |
| Astrocytic Glutamate-Glutamine Uptake And Metabolism | R-HSA-210455 | 3.750822e-01 | 0.426 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 3.750822e-01 | 0.426 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 2.578630e-01 | 0.589 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 1.846810e-01 | 0.734 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 2.450581e-01 | 0.611 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 2.564045e-01 | 0.591 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 3.139317e-01 | 0.503 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 2.745375e-01 | 0.561 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 3.506902e-01 | 0.455 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 2.734377e-01 | 0.563 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 3.154644e-01 | 0.501 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 1.518950e-01 | 0.818 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 1.649544e-01 | 0.783 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 1.418714e-01 | 0.848 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 2.908113e-01 | 0.536 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 1.923754e-01 | 0.716 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 2.564045e-01 | 0.591 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 2.908113e-01 | 0.536 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 2.169452e-01 | 0.664 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 2.019133e-01 | 0.695 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 1.457502e-01 | 0.836 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 2.735908e-01 | 0.563 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 1.954062e-01 | 0.709 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 1.361154e-01 | 0.866 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 3.506902e-01 | 0.455 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 1.473810e-01 | 0.832 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 1.923754e-01 | 0.716 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 1.354790e-01 | 0.868 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 2.895698e-01 | 0.538 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 1.649544e-01 | 0.783 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 3.192990e-01 | 0.496 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 3.192990e-01 | 0.496 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 2.108846e-01 | 0.676 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 2.108846e-01 | 0.676 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 3.477858e-01 | 0.459 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 2.375409e-01 | 0.624 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 2.430634e-01 | 0.614 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 3.403598e-01 | 0.468 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 1.821544e-01 | 0.740 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 1.370435e-01 | 0.863 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 2.561215e-01 | 0.592 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 3.255117e-01 | 0.487 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 3.687872e-01 | 0.433 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 1.954062e-01 | 0.709 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 2.065376e-01 | 0.685 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 2.792938e-01 | 0.554 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 1.418714e-01 | 0.848 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 2.706937e-01 | 0.568 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 3.486578e-01 | 0.458 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 3.462754e-01 | 0.461 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 2.585442e-01 | 0.587 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 1.354790e-01 | 0.868 | 0 | 0 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660825 | 2.895698e-01 | 0.538 | 0 | 0 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660826 | 2.895698e-01 | 0.538 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 2.264775e-01 | 0.645 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 2.893031e-01 | 0.539 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 1.312387e-01 | 0.882 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 3.360963e-01 | 0.474 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 3.360963e-01 | 0.474 | 0 | 0 |
| S Phase | R-HSA-69242 | 2.824015e-01 | 0.549 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 2.797265e-01 | 0.553 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 1.687058e-01 | 0.773 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 1.687058e-01 | 0.773 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 1.687058e-01 | 0.773 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 1.687058e-01 | 0.773 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 2.240413e-01 | 0.650 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 2.893031e-01 | 0.539 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 1.687058e-01 | 0.773 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 3.667906e-01 | 0.436 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 2.895698e-01 | 0.538 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 1.687584e-01 | 0.773 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 2.284804e-01 | 0.641 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 2.375409e-01 | 0.624 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 1.776013e-01 | 0.751 | 0 | 0 |
| Vitamin D (calciferol) metabolism | R-HSA-196791 | 2.578630e-01 | 0.589 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 2.735908e-01 | 0.563 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 2.588969e-01 | 0.587 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 3.238982e-01 | 0.490 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 3.238982e-01 | 0.490 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 3.238982e-01 | 0.490 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 2.767550e-01 | 0.558 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 3.537683e-01 | 0.451 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 3.449427e-01 | 0.462 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 2.995248e-01 | 0.524 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 2.585442e-01 | 0.587 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 1.354790e-01 | 0.868 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 2.895698e-01 | 0.538 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 2.735908e-01 | 0.563 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 2.073611e-01 | 0.683 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 3.667906e-01 | 0.436 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 3.667906e-01 | 0.436 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 1.762743e-01 | 0.754 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 3.477858e-01 | 0.459 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 2.578630e-01 | 0.589 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 2.115737e-01 | 0.675 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 3.049738e-01 | 0.516 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 2.125297e-01 | 0.673 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 3.515063e-01 | 0.454 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 2.591168e-01 | 0.587 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 1.289310e-01 | 0.890 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 2.433951e-01 | 0.614 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 2.912336e-01 | 0.536 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 1.649544e-01 | 0.783 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 3.750822e-01 | 0.426 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 3.205788e-01 | 0.494 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 2.449156e-01 | 0.611 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 1.649544e-01 | 0.783 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 2.421482e-01 | 0.616 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 2.578630e-01 | 0.589 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 3.205788e-01 | 0.494 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 1.800819e-01 | 0.745 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 1.415523e-01 | 0.849 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 2.019133e-01 | 0.695 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 2.735908e-01 | 0.563 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 2.087764e-01 | 0.680 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 3.192183e-01 | 0.496 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 3.667906e-01 | 0.436 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 3.760311e-01 | 0.425 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 3.767412e-01 | 0.424 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 3.794512e-01 | 0.421 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 3.819328e-01 | 0.418 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 3.819328e-01 | 0.418 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 3.819328e-01 | 0.418 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 3.819328e-01 | 0.418 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 3.819328e-01 | 0.418 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 3.819328e-01 | 0.418 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 3.826964e-01 | 0.417 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 3.838308e-01 | 0.416 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 3.907107e-01 | 0.408 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 3.939922e-01 | 0.405 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 3.946214e-01 | 0.404 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 3.946214e-01 | 0.404 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 3.969181e-01 | 0.401 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 3.969181e-01 | 0.401 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 3.969181e-01 | 0.401 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 3.969181e-01 | 0.401 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 3.969181e-01 | 0.401 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 3.969181e-01 | 0.401 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 4.012377e-01 | 0.397 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 4.012377e-01 | 0.397 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 4.012377e-01 | 0.397 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 4.012377e-01 | 0.397 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 4.012377e-01 | 0.397 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 4.012377e-01 | 0.397 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 4.012377e-01 | 0.397 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 4.012377e-01 | 0.397 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 4.012377e-01 | 0.397 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 4.012377e-01 | 0.397 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 4.012377e-01 | 0.397 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 4.012377e-01 | 0.397 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 4.012377e-01 | 0.397 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 4.012377e-01 | 0.397 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 4.012377e-01 | 0.397 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 4.044953e-01 | 0.393 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 4.059923e-01 | 0.391 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 4.059923e-01 | 0.391 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 4.059923e-01 | 0.391 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 4.063936e-01 | 0.391 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 4.063936e-01 | 0.391 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 4.080777e-01 | 0.389 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 4.080777e-01 | 0.389 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 4.117331e-01 | 0.385 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 4.117331e-01 | 0.385 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 4.117331e-01 | 0.385 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 4.117331e-01 | 0.385 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 4.117331e-01 | 0.385 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 4.139030e-01 | 0.383 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 4.151129e-01 | 0.382 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 4.172992e-01 | 0.380 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 4.179832e-01 | 0.379 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 4.214022e-01 | 0.375 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 4.214022e-01 | 0.375 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 4.251458e-01 | 0.371 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 4.263001e-01 | 0.370 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 4.263001e-01 | 0.370 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 4.263001e-01 | 0.370 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 4.263001e-01 | 0.370 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 4.263001e-01 | 0.370 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 4.263658e-01 | 0.370 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 4.263658e-01 | 0.370 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 4.263658e-01 | 0.370 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 4.263658e-01 | 0.370 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 4.263658e-01 | 0.370 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 4.263658e-01 | 0.370 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 4.263658e-01 | 0.370 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 4.263658e-01 | 0.370 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 4.263658e-01 | 0.370 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 4.263658e-01 | 0.370 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 4.270184e-01 | 0.370 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 4.270184e-01 | 0.370 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 4.274634e-01 | 0.369 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 4.359600e-01 | 0.361 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 4.438141e-01 | 0.353 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 4.457164e-01 | 0.351 | 0 | 0 |
| Presynaptic depolarization and calcium channel opening | R-HSA-112308 | 4.503148e-01 | 0.346 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 4.503148e-01 | 0.346 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 4.503148e-01 | 0.346 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 4.512479e-01 | 0.346 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 4.550429e-01 | 0.342 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 4.550429e-01 | 0.342 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 4.551203e-01 | 0.342 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 4.597133e-01 | 0.338 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 4.655621e-01 | 0.332 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 4.660465e-01 | 0.332 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 4.690695e-01 | 0.329 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 4.723522e-01 | 0.326 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 4.723522e-01 | 0.326 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 4.726348e-01 | 0.325 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 4.726348e-01 | 0.325 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 4.733258e-01 | 0.325 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 4.733258e-01 | 0.325 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 4.733258e-01 | 0.325 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 4.733258e-01 | 0.325 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 4.733258e-01 | 0.325 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 4.733258e-01 | 0.325 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 4.733258e-01 | 0.325 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 4.733258e-01 | 0.325 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 4.735992e-01 | 0.325 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 4.736929e-01 | 0.325 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 4.796842e-01 | 0.319 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 4.820828e-01 | 0.317 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 4.828781e-01 | 0.316 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 4.834198e-01 | 0.316 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 4.898311e-01 | 0.310 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 4.917966e-01 | 0.308 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 4.953059e-01 | 0.305 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 4.953747e-01 | 0.305 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 4.953747e-01 | 0.305 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 4.953747e-01 | 0.305 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 4.953747e-01 | 0.305 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 4.953747e-01 | 0.305 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 4.953747e-01 | 0.305 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 4.953747e-01 | 0.305 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 4.953747e-01 | 0.305 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 4.953747e-01 | 0.305 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 4.953747e-01 | 0.305 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 4.953747e-01 | 0.305 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 4.953747e-01 | 0.305 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 4.953747e-01 | 0.305 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 4.953747e-01 | 0.305 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 4.953747e-01 | 0.305 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 4.953747e-01 | 0.305 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 4.953747e-01 | 0.305 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 4.953747e-01 | 0.305 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 4.964622e-01 | 0.304 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 4.964622e-01 | 0.304 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 4.964622e-01 | 0.304 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 4.964622e-01 | 0.304 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 5.025383e-01 | 0.299 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 5.046662e-01 | 0.297 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 5.057877e-01 | 0.296 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 5.098082e-01 | 0.293 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 5.098082e-01 | 0.293 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 5.098166e-01 | 0.293 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 5.098166e-01 | 0.293 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 5.098166e-01 | 0.293 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 5.151187e-01 | 0.288 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 5.151187e-01 | 0.288 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 5.151187e-01 | 0.288 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 5.165019e-01 | 0.287 | 0 | 0 |
| PDH complex synthesizes acetyl-CoA from PYR | R-HSA-9861559 | 5.165019e-01 | 0.287 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 5.165019e-01 | 0.287 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 5.165019e-01 | 0.287 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 5.165019e-01 | 0.287 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 5.165019e-01 | 0.287 | 0 | 0 |
| Diseases of nucleotide metabolism | R-HSA-9735804 | 5.165019e-01 | 0.287 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 5.165019e-01 | 0.287 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 5.165019e-01 | 0.287 | 0 | 0 |
| Reversible hydration of carbon dioxide | R-HSA-1475029 | 5.165019e-01 | 0.287 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 5.165019e-01 | 0.287 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 5.165019e-01 | 0.287 | 0 | 0 |
| Acyl chain remodeling of DAG and TAG | R-HSA-1482883 | 5.165019e-01 | 0.287 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 5.165019e-01 | 0.287 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 5.186850e-01 | 0.285 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 5.229367e-01 | 0.282 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 5.229367e-01 | 0.282 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 5.239611e-01 | 0.281 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 5.274856e-01 | 0.278 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 5.274856e-01 | 0.278 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 5.310811e-01 | 0.275 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 5.356630e-01 | 0.271 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 5.356630e-01 | 0.271 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 5.358186e-01 | 0.271 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 5.367458e-01 | 0.270 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 5.367458e-01 | 0.270 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 5.367458e-01 | 0.270 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 5.367458e-01 | 0.270 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 5.367458e-01 | 0.270 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 5.381114e-01 | 0.269 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 5.415284e-01 | 0.266 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 5.457479e-01 | 0.263 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 5.484594e-01 | 0.261 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 5.484594e-01 | 0.261 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 5.520341e-01 | 0.258 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 5.534042e-01 | 0.257 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 5.557039e-01 | 0.255 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 5.561433e-01 | 0.255 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 5.561433e-01 | 0.255 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 5.561433e-01 | 0.255 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 5.561433e-01 | 0.255 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 5.561433e-01 | 0.255 | 0 | 0 |
| Transport and metabolism of PAPS | R-HSA-174362 | 5.561433e-01 | 0.255 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 5.561433e-01 | 0.255 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 5.561433e-01 | 0.255 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 5.561433e-01 | 0.255 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 5.561433e-01 | 0.255 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 5.561433e-01 | 0.255 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 5.578790e-01 | 0.253 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 5.599391e-01 | 0.252 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 5.608566e-01 | 0.251 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 5.608566e-01 | 0.251 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 5.608566e-01 | 0.251 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 5.608566e-01 | 0.251 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 5.618746e-01 | 0.250 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 5.655283e-01 | 0.248 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 5.730085e-01 | 0.242 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 5.730085e-01 | 0.242 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 5.740921e-01 | 0.241 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 5.747297e-01 | 0.241 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 5.747297e-01 | 0.241 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 5.747297e-01 | 0.241 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 5.747297e-01 | 0.241 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 5.747297e-01 | 0.241 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 5.747297e-01 | 0.241 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 5.747297e-01 | 0.241 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 5.747297e-01 | 0.241 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 5.747297e-01 | 0.241 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 5.752187e-01 | 0.240 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 5.752187e-01 | 0.240 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 5.752187e-01 | 0.240 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 5.849139e-01 | 0.233 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 5.849139e-01 | 0.233 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 5.849139e-01 | 0.233 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 5.925388e-01 | 0.227 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 5.925388e-01 | 0.227 | 0 | 0 |
| Scavenging by Class B Receptors | R-HSA-3000471 | 5.925388e-01 | 0.227 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 5.925388e-01 | 0.227 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 5.925388e-01 | 0.227 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 5.925388e-01 | 0.227 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 5.925388e-01 | 0.227 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 5.941891e-01 | 0.226 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 5.965720e-01 | 0.224 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 5.965720e-01 | 0.224 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 5.965720e-01 | 0.224 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 5.965720e-01 | 0.224 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 5.983517e-01 | 0.223 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 6.022674e-01 | 0.220 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 6.024139e-01 | 0.220 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 6.028671e-01 | 0.220 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 6.079828e-01 | 0.216 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 6.079828e-01 | 0.216 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 6.096032e-01 | 0.215 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 6.096032e-01 | 0.215 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 6.096032e-01 | 0.215 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 6.096032e-01 | 0.215 | 0 | 0 |
| Metabolism of ingested H2SeO4 and H2SeO3 into H2Se | R-HSA-2408550 | 6.096032e-01 | 0.215 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 6.096032e-01 | 0.215 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 6.096032e-01 | 0.215 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 6.121370e-01 | 0.213 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 6.178544e-01 | 0.209 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 6.191466e-01 | 0.208 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 6.191466e-01 | 0.208 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 6.197845e-01 | 0.208 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 6.248918e-01 | 0.204 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 6.259540e-01 | 0.203 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 6.259540e-01 | 0.203 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 6.259540e-01 | 0.203 | 0 | 0 |
| PKA activation | R-HSA-163615 | 6.259540e-01 | 0.203 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 6.259540e-01 | 0.203 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 6.259540e-01 | 0.203 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 6.300639e-01 | 0.201 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 6.300639e-01 | 0.201 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 6.300639e-01 | 0.201 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 6.300639e-01 | 0.201 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 6.300639e-01 | 0.201 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 6.391487e-01 | 0.194 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 6.407358e-01 | 0.193 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 6.407358e-01 | 0.193 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 6.416209e-01 | 0.193 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 6.416209e-01 | 0.193 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 6.416209e-01 | 0.193 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 6.416209e-01 | 0.193 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 6.416209e-01 | 0.193 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 6.416209e-01 | 0.193 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 6.452187e-01 | 0.190 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 6.477093e-01 | 0.189 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 6.477093e-01 | 0.189 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 6.511637e-01 | 0.186 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 6.511637e-01 | 0.186 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 6.511637e-01 | 0.186 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 6.511637e-01 | 0.186 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 6.566325e-01 | 0.183 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 6.566325e-01 | 0.183 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 6.566325e-01 | 0.183 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 6.583801e-01 | 0.182 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 6.613494e-01 | 0.180 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 6.613494e-01 | 0.180 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 6.613494e-01 | 0.180 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 6.613494e-01 | 0.180 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 6.641522e-01 | 0.178 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 6.710162e-01 | 0.173 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 6.710162e-01 | 0.173 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 6.710162e-01 | 0.173 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 6.710162e-01 | 0.173 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 6.710162e-01 | 0.173 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 6.710162e-01 | 0.173 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 6.710162e-01 | 0.173 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 6.712949e-01 | 0.173 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 6.712949e-01 | 0.173 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 6.729734e-01 | 0.172 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 6.847982e-01 | 0.164 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 6.847982e-01 | 0.164 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 6.847982e-01 | 0.164 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 6.847982e-01 | 0.164 | 0 | 0 |
| Serine metabolism | R-HSA-977347 | 6.847982e-01 | 0.164 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 6.847982e-01 | 0.164 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 6.847982e-01 | 0.164 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 6.883325e-01 | 0.162 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 6.883325e-01 | 0.162 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 6.904741e-01 | 0.161 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 6.904741e-01 | 0.161 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 6.939344e-01 | 0.159 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 6.939344e-01 | 0.159 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 6.960216e-01 | 0.157 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 6.980036e-01 | 0.156 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 6.980036e-01 | 0.156 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 6.980036e-01 | 0.156 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 6.980036e-01 | 0.156 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 6.980036e-01 | 0.156 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 6.980036e-01 | 0.156 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 6.980036e-01 | 0.156 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 6.997131e-01 | 0.155 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 6.997131e-01 | 0.155 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 7.014808e-01 | 0.154 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 7.035663e-01 | 0.153 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 7.073405e-01 | 0.150 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 7.106565e-01 | 0.148 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 7.106565e-01 | 0.148 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 7.106565e-01 | 0.148 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 7.106565e-01 | 0.148 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 7.106565e-01 | 0.148 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 7.106565e-01 | 0.148 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 7.109673e-01 | 0.148 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 7.123397e-01 | 0.147 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 7.123397e-01 | 0.147 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 7.175043e-01 | 0.144 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 7.209585e-01 | 0.142 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 7.227801e-01 | 0.141 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 7.227801e-01 | 0.141 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 7.227801e-01 | 0.141 | 0 | 0 |
| TNFs bind their physiological receptors | R-HSA-5669034 | 7.227801e-01 | 0.141 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 7.228043e-01 | 0.141 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 7.228043e-01 | 0.141 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 7.235981e-01 | 0.141 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 7.250020e-01 | 0.140 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 7.260627e-01 | 0.139 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 7.260627e-01 | 0.139 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 7.260627e-01 | 0.139 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 7.260627e-01 | 0.139 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 7.269263e-01 | 0.139 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 7.330601e-01 | 0.135 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 7.343964e-01 | 0.134 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 7.343964e-01 | 0.134 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 7.343964e-01 | 0.134 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 7.343964e-01 | 0.134 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 7.343964e-01 | 0.134 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 7.343964e-01 | 0.134 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 7.343964e-01 | 0.134 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 7.344006e-01 | 0.134 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 7.344006e-01 | 0.134 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 7.391504e-01 | 0.131 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 7.417891e-01 | 0.130 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 7.417936e-01 | 0.130 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 7.427047e-01 | 0.129 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 7.455266e-01 | 0.128 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 7.455266e-01 | 0.128 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 7.455266e-01 | 0.128 | 0 | 0 |
| Attachment of bacteria to epithelial cells | R-HSA-9638630 | 7.455266e-01 | 0.128 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 7.455266e-01 | 0.128 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 7.455266e-01 | 0.128 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 7.455266e-01 | 0.128 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 7.455266e-01 | 0.128 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 7.504291e-01 | 0.125 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 7.504291e-01 | 0.125 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 7.534101e-01 | 0.123 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 7.561910e-01 | 0.121 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 7.561910e-01 | 0.121 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 7.561910e-01 | 0.121 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 7.561910e-01 | 0.121 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 7.561910e-01 | 0.121 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 7.561910e-01 | 0.121 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 7.561910e-01 | 0.121 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 7.561910e-01 | 0.121 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 7.581268e-01 | 0.120 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 7.581268e-01 | 0.120 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 7.588245e-01 | 0.120 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 7.622033e-01 | 0.118 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 7.646205e-01 | 0.117 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 7.656183e-01 | 0.116 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 7.664092e-01 | 0.116 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 7.664092e-01 | 0.116 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 7.664092e-01 | 0.116 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 7.715651e-01 | 0.113 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 7.721785e-01 | 0.112 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 7.729075e-01 | 0.112 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 7.761997e-01 | 0.110 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 7.761997e-01 | 0.110 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 7.761997e-01 | 0.110 | 0 | 0 |
| Thyroxine biosynthesis | R-HSA-209968 | 7.761997e-01 | 0.110 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 7.761997e-01 | 0.110 | 0 | 0 |
| Regulation of pyruvate dehydrogenase (PDH) complex | R-HSA-204174 | 7.761997e-01 | 0.110 | 0 | 0 |
| Activation of Matrix Metalloproteinases | R-HSA-1592389 | 7.761997e-01 | 0.110 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 7.761997e-01 | 0.110 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 7.761997e-01 | 0.110 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 7.761997e-01 | 0.110 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 7.799981e-01 | 0.108 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 7.831712e-01 | 0.106 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 7.855804e-01 | 0.105 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 7.855804e-01 | 0.105 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 7.855804e-01 | 0.105 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 7.855804e-01 | 0.105 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 7.855804e-01 | 0.105 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 7.855804e-01 | 0.105 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 7.855804e-01 | 0.105 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 7.855804e-01 | 0.105 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 7.855804e-01 | 0.105 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 7.864410e-01 | 0.104 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 7.935988e-01 | 0.100 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 7.935988e-01 | 0.100 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 7.935988e-01 | 0.100 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 7.935988e-01 | 0.100 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 7.935988e-01 | 0.100 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 7.945635e-01 | 0.100 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 7.945635e-01 | 0.100 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 7.945635e-01 | 0.100 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 7.945684e-01 | 0.100 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 7.945684e-01 | 0.100 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 7.945684e-01 | 0.100 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 7.945684e-01 | 0.100 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 7.965955e-01 | 0.099 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 8.001166e-01 | 0.097 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 8.031803e-01 | 0.095 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 8.031803e-01 | 0.095 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 8.031803e-01 | 0.095 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 8.044542e-01 | 0.094 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 8.114316e-01 | 0.091 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 8.114316e-01 | 0.091 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 8.114316e-01 | 0.091 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 8.114316e-01 | 0.091 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 8.114316e-01 | 0.091 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 8.114316e-01 | 0.091 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 8.114578e-01 | 0.091 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 8.185870e-01 | 0.087 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 8.193375e-01 | 0.087 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 8.193375e-01 | 0.087 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 8.193375e-01 | 0.087 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 8.193375e-01 | 0.087 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 8.243956e-01 | 0.084 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 8.256607e-01 | 0.083 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 8.269123e-01 | 0.083 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 8.269123e-01 | 0.083 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 8.269123e-01 | 0.083 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 8.269123e-01 | 0.083 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 8.269123e-01 | 0.083 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 8.269123e-01 | 0.083 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 8.269123e-01 | 0.083 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 8.269123e-01 | 0.083 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 8.269123e-01 | 0.083 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 8.269123e-01 | 0.083 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 8.276034e-01 | 0.082 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 8.300366e-01 | 0.081 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 8.316911e-01 | 0.080 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 8.318953e-01 | 0.080 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 8.331665e-01 | 0.079 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 8.341701e-01 | 0.079 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 8.341701e-01 | 0.079 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 8.355139e-01 | 0.078 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 8.357521e-01 | 0.078 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 8.411239e-01 | 0.075 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 8.411239e-01 | 0.075 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 8.411239e-01 | 0.075 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 8.411239e-01 | 0.075 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 8.411239e-01 | 0.075 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 8.411239e-01 | 0.075 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 8.411239e-01 | 0.075 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 8.442561e-01 | 0.074 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 8.459921e-01 | 0.073 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 8.459921e-01 | 0.073 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 8.477865e-01 | 0.072 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 8.477865e-01 | 0.072 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 8.477865e-01 | 0.072 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 8.486023e-01 | 0.071 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 8.510007e-01 | 0.070 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 8.510007e-01 | 0.070 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 8.531538e-01 | 0.069 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 8.541701e-01 | 0.068 | 0 | 0 |
| Depurination | R-HSA-73927 | 8.541701e-01 | 0.068 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 8.541701e-01 | 0.068 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 8.541701e-01 | 0.068 | 0 | 0 |
| Biofilm formation | R-HSA-9931953 | 8.541701e-01 | 0.068 | 0 | 0 |
| alpha-linolenic acid (ALA) metabolism | R-HSA-2046106 | 8.541701e-01 | 0.068 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 8.558605e-01 | 0.068 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 8.602864e-01 | 0.065 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 8.602864e-01 | 0.065 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 8.610135e-01 | 0.065 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 8.651484e-01 | 0.063 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 8.661465e-01 | 0.062 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 8.661465e-01 | 0.062 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 8.717611e-01 | 0.060 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 8.717611e-01 | 0.060 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 8.771406e-01 | 0.057 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 8.771406e-01 | 0.057 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 8.771406e-01 | 0.057 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 8.771406e-01 | 0.057 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 8.771406e-01 | 0.057 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 8.780545e-01 | 0.056 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 8.820969e-01 | 0.054 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 8.820969e-01 | 0.054 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 8.822947e-01 | 0.054 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 8.822947e-01 | 0.054 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 8.822947e-01 | 0.054 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 8.828063e-01 | 0.054 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 8.918014e-01 | 0.050 | 0 | 0 |
| Methylation | R-HSA-156581 | 8.919642e-01 | 0.050 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 8.919642e-01 | 0.050 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 8.919642e-01 | 0.050 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 8.964973e-01 | 0.047 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 8.964973e-01 | 0.047 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 8.964973e-01 | 0.047 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 8.964973e-01 | 0.047 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 8.964973e-01 | 0.047 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 8.991908e-01 | 0.046 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 9.001360e-01 | 0.046 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 9.008404e-01 | 0.045 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.008404e-01 | 0.045 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 9.008404e-01 | 0.045 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 9.021453e-01 | 0.045 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 9.038569e-01 | 0.044 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.038569e-01 | 0.044 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 9.050016e-01 | 0.043 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 9.050016e-01 | 0.043 | 0 | 0 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | R-HSA-2046104 | 9.050016e-01 | 0.043 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 9.053732e-01 | 0.043 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 9.070972e-01 | 0.042 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.078210e-01 | 0.042 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 9.082264e-01 | 0.042 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 9.105456e-01 | 0.041 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 9.128080e-01 | 0.040 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 9.128080e-01 | 0.040 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 9.132737e-01 | 0.039 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.132737e-01 | 0.039 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 9.164676e-01 | 0.038 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 9.233331e-01 | 0.035 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 9.260446e-01 | 0.033 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 9.265515e-01 | 0.033 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.265515e-01 | 0.033 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 9.270705e-01 | 0.033 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 9.296351e-01 | 0.032 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.319869e-01 | 0.031 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 9.325775e-01 | 0.030 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 9.325893e-01 | 0.030 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.343259e-01 | 0.030 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.354197e-01 | 0.029 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 9.354197e-01 | 0.029 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 9.381314e-01 | 0.028 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 9.407294e-01 | 0.027 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 9.429414e-01 | 0.026 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.432185e-01 | 0.025 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.432185e-01 | 0.025 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.448077e-01 | 0.025 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 9.456031e-01 | 0.024 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 9.456031e-01 | 0.024 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 9.456031e-01 | 0.024 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.456031e-01 | 0.024 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 9.468353e-01 | 0.024 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 9.470840e-01 | 0.024 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 9.570545e-01 | 0.019 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 9.585637e-01 | 0.018 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 9.585637e-01 | 0.018 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 9.597183e-01 | 0.018 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.597183e-01 | 0.018 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.597183e-01 | 0.018 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.603205e-01 | 0.018 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.616706e-01 | 0.017 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 9.627923e-01 | 0.016 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.645859e-01 | 0.016 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 9.660742e-01 | 0.015 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.660742e-01 | 0.015 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 9.660742e-01 | 0.015 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 9.675000e-01 | 0.014 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 9.675000e-01 | 0.014 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.675000e-01 | 0.014 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 9.675000e-01 | 0.014 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 9.688660e-01 | 0.014 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.691425e-01 | 0.014 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 9.701747e-01 | 0.013 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 9.714284e-01 | 0.013 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.740953e-01 | 0.011 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.740953e-01 | 0.011 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.746230e-01 | 0.011 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 9.748826e-01 | 0.011 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 9.759387e-01 | 0.011 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.762349e-01 | 0.010 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 9.769504e-01 | 0.010 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 9.770039e-01 | 0.010 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 9.779197e-01 | 0.010 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.792003e-01 | 0.009 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 9.797378e-01 | 0.009 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 9.797378e-01 | 0.009 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 9.821886e-01 | 0.008 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.836556e-01 | 0.007 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 9.836556e-01 | 0.007 | 0 | 0 |
| Translation | R-HSA-72766 | 9.847914e-01 | 0.007 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.848275e-01 | 0.007 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 9.861451e-01 | 0.006 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.871382e-01 | 0.006 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.873716e-01 | 0.006 | 0 | 0 |
| Immune System | R-HSA-168256 | 9.876014e-01 | 0.005 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 9.879031e-01 | 0.005 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.884122e-01 | 0.005 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.898149e-01 | 0.004 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.898149e-01 | 0.004 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.900547e-01 | 0.004 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 9.908130e-01 | 0.004 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 9.908130e-01 | 0.004 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 9.908130e-01 | 0.004 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.912945e-01 | 0.004 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 9.914249e-01 | 0.004 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 9.914915e-01 | 0.004 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.917277e-01 | 0.004 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.930848e-01 | 0.003 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 9.944238e-01 | 0.002 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.945854e-01 | 0.002 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.952471e-01 | 0.002 | 0 | 0 |
| Disease | R-HSA-1643685 | 9.954066e-01 | 0.002 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 9.961065e-01 | 0.002 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 9.961065e-01 | 0.002 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.963120e-01 | 0.002 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.963749e-01 | 0.002 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 9.972006e-01 | 0.001 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.973187e-01 | 0.001 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.974076e-01 | 0.001 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.975758e-01 | 0.001 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.975758e-01 | 0.001 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.976439e-01 | 0.001 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.977065e-01 | 0.001 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.979297e-01 | 0.001 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.979394e-01 | 0.001 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 9.981809e-01 | 0.001 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 9.985081e-01 | 0.001 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.985340e-01 | 0.001 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 9.987266e-01 | 0.001 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 9.988704e-01 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.992375e-01 | 0.000 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 9.995016e-01 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.996829e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.997514e-01 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.998189e-01 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 9.998250e-01 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 9.998381e-01 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 9.998903e-01 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.998926e-01 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 9.999289e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.999402e-01 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 9.999418e-01 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.999779e-01 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 9.999884e-01 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 9.999974e-01 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 9.999980e-01 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 9.999992e-01 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 9.999998e-01 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 9.999999e-01 | 0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Peptide chain elongation | R-HSA-156902 | 1.110223e-16 | 15.955 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 1.110223e-16 | 15.955 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 1.110223e-16 | 15.955 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 1.110223e-16 | 15.955 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 1.110223e-16 | 15.955 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 1.110223e-16 | 15.955 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 1.110223e-16 | 15.955 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 1.110223e-16 | 15.955 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 1.110223e-16 | 15.955 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 1.110223e-16 | 15.955 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 1.110223e-16 | 15.955 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 1.110223e-16 | 15.955 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 1.110223e-16 | 15.955 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 1.110223e-16 | 15.955 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 1.110223e-16 | 15.955 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 1.110223e-16 | 15.955 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 4.440892e-16 | 15.353 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 6.661338e-16 | 15.176 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 1.554312e-15 | 14.808 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 5.995204e-15 | 14.222 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 5.662137e-15 | 14.247 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 5.995204e-15 | 14.222 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 1.820766e-14 | 13.740 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 2.065015e-14 | 13.685 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 1.203482e-13 | 12.920 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 4.787282e-13 | 12.320 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 4.130252e-12 | 11.384 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 5.261014e-12 | 11.279 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 5.353828e-12 | 11.271 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 1.117284e-11 | 10.952 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 5.371248e-11 | 10.270 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 1.806876e-10 | 9.743 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 7.597595e-10 | 9.119 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 3.086350e-09 | 8.511 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 5.340151e-09 | 8.272 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 6.549074e-09 | 8.184 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 1.056156e-08 | 7.976 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 1.242959e-08 | 7.906 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 1.538356e-08 | 7.813 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 1.673585e-08 | 7.776 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 3.399100e-08 | 7.469 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 3.511526e-08 | 7.455 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 1.612095e-07 | 6.793 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 3.274018e-07 | 6.485 | 0 | 0 |
| Translation | R-HSA-72766 | 3.926989e-07 | 6.406 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 4.504242e-07 | 6.346 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 1.116645e-06 | 5.952 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 2.578967e-06 | 5.589 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 2.752929e-06 | 5.560 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 2.818630e-06 | 5.550 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 3.147185e-06 | 5.502 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 4.762252e-06 | 5.322 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 5.721525e-06 | 5.242 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 6.909244e-06 | 5.161 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 7.225142e-06 | 5.141 | 0 | 0 |
| M Phase | R-HSA-68886 | 1.504304e-05 | 4.823 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 1.860603e-05 | 4.730 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 1.971143e-05 | 4.705 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 2.224350e-05 | 4.653 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 2.741254e-05 | 4.562 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 2.756759e-05 | 4.560 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 2.756759e-05 | 4.560 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 3.231065e-05 | 4.491 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 3.829062e-05 | 4.417 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 5.166624e-05 | 4.287 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 5.692661e-05 | 4.245 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 6.390220e-05 | 4.194 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 6.728646e-05 | 4.172 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 8.212185e-05 | 4.086 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 9.652339e-05 | 4.015 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 1.071664e-04 | 3.970 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 1.543189e-04 | 3.812 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 3.052239e-04 | 3.515 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 3.846303e-04 | 3.415 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 4.046204e-04 | 3.393 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 4.359766e-04 | 3.361 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 4.610764e-04 | 3.336 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 4.766949e-04 | 3.322 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 5.079795e-04 | 3.294 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 4.882824e-04 | 3.311 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 5.491347e-04 | 3.260 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 5.491347e-04 | 3.260 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 5.491347e-04 | 3.260 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 5.491347e-04 | 3.260 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 5.195682e-04 | 3.284 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 5.195682e-04 | 3.284 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 6.008389e-04 | 3.221 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 6.198403e-04 | 3.208 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 6.198403e-04 | 3.208 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 8.145548e-04 | 3.089 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 1.013527e-03 | 2.994 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 1.081530e-03 | 2.966 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 1.182615e-03 | 2.927 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 1.188054e-03 | 2.925 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 1.239893e-03 | 2.907 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 1.241207e-03 | 2.906 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 1.370264e-03 | 2.863 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 1.385728e-03 | 2.858 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 1.512373e-03 | 2.820 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 1.569617e-03 | 2.804 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 1.575747e-03 | 2.803 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 1.608667e-03 | 2.794 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 1.617559e-03 | 2.791 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 1.617559e-03 | 2.791 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 1.724120e-03 | 2.763 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 1.840340e-03 | 2.735 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 1.864916e-03 | 2.729 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 1.920315e-03 | 2.717 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 1.959574e-03 | 2.708 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 2.114129e-03 | 2.675 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 2.139263e-03 | 2.670 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 2.207719e-03 | 2.656 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 2.264088e-03 | 2.645 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 2.595137e-03 | 2.586 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 2.632032e-03 | 2.580 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 2.798546e-03 | 2.553 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 2.948913e-03 | 2.530 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 2.954535e-03 | 2.530 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 3.108936e-03 | 2.507 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 3.108936e-03 | 2.507 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 3.128575e-03 | 2.505 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 3.128575e-03 | 2.505 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 3.182640e-03 | 2.497 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 3.182640e-03 | 2.497 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 3.532642e-03 | 2.452 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 3.520484e-03 | 2.453 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 3.473164e-03 | 2.459 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 3.606481e-03 | 2.443 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 3.657983e-03 | 2.437 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 3.768516e-03 | 2.424 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 4.126088e-03 | 2.384 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 4.380290e-03 | 2.358 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 4.390625e-03 | 2.357 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 4.814842e-03 | 2.317 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 4.743079e-03 | 2.324 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 4.914973e-03 | 2.308 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 4.676974e-03 | 2.330 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 4.762053e-03 | 2.322 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 5.143393e-03 | 2.289 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 5.543753e-03 | 2.256 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 5.551446e-03 | 2.256 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 5.909023e-03 | 2.228 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 6.212695e-03 | 2.207 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 6.440812e-03 | 2.191 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 6.591005e-03 | 2.181 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 6.652326e-03 | 2.177 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 7.104978e-03 | 2.148 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 7.104978e-03 | 2.148 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 6.903518e-03 | 2.161 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 7.429339e-03 | 2.129 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 7.104978e-03 | 2.148 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 7.916089e-03 | 2.101 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 8.199067e-03 | 2.086 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 8.360526e-03 | 2.078 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 8.483110e-03 | 2.071 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 8.522891e-03 | 2.069 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 8.972541e-03 | 2.047 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 8.972541e-03 | 2.047 | 0 | 0 |
| Kinesins | R-HSA-983189 | 8.972541e-03 | 2.047 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 9.140233e-03 | 2.039 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 9.574594e-03 | 2.019 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 9.654088e-03 | 2.015 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 1.104807e-02 | 1.957 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 1.104807e-02 | 1.957 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 1.048666e-02 | 1.979 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 1.059156e-02 | 1.975 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 9.796171e-03 | 2.009 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 1.092533e-02 | 1.962 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 1.031859e-02 | 1.986 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 1.002701e-02 | 1.999 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 1.017750e-02 | 1.992 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 1.106157e-02 | 1.956 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 1.116894e-02 | 1.952 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 1.132021e-02 | 1.946 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 1.140353e-02 | 1.943 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 1.161286e-02 | 1.935 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 1.161286e-02 | 1.935 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 1.216927e-02 | 1.915 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 1.249088e-02 | 1.903 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 1.249088e-02 | 1.903 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 1.249088e-02 | 1.903 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 1.258961e-02 | 1.900 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 1.330003e-02 | 1.876 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 1.399472e-02 | 1.854 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 1.399879e-02 | 1.854 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 1.412068e-02 | 1.850 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 1.496396e-02 | 1.825 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 1.576372e-02 | 1.802 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 1.663097e-02 | 1.779 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 1.506150e-02 | 1.822 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 1.496396e-02 | 1.825 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 1.451559e-02 | 1.838 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 1.506150e-02 | 1.822 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 1.685755e-02 | 1.773 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 1.702705e-02 | 1.769 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 1.724561e-02 | 1.763 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 1.760389e-02 | 1.754 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 1.760389e-02 | 1.754 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 1.767189e-02 | 1.753 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 1.807225e-02 | 1.743 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 1.807290e-02 | 1.743 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 1.919503e-02 | 1.717 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 1.919503e-02 | 1.717 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 1.958627e-02 | 1.708 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 1.958627e-02 | 1.708 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 1.958627e-02 | 1.708 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 2.009712e-02 | 1.697 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 2.401947e-02 | 1.619 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 2.401947e-02 | 1.619 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 2.219194e-02 | 1.654 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 2.219194e-02 | 1.654 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 2.171534e-02 | 1.663 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 2.401299e-02 | 1.620 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 2.401299e-02 | 1.620 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 2.394147e-02 | 1.621 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 2.113108e-02 | 1.675 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 2.279178e-02 | 1.642 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 2.401947e-02 | 1.619 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 2.078809e-02 | 1.682 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 2.196109e-02 | 1.658 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 2.253868e-02 | 1.647 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 2.399534e-02 | 1.620 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 2.399534e-02 | 1.620 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 2.122164e-02 | 1.673 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 2.326958e-02 | 1.633 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 2.499270e-02 | 1.602 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 2.604126e-02 | 1.584 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 2.643020e-02 | 1.578 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 2.725767e-02 | 1.565 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 2.798764e-02 | 1.553 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 2.816462e-02 | 1.550 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 2.826333e-02 | 1.549 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 2.864786e-02 | 1.543 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 2.895373e-02 | 1.538 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 2.902357e-02 | 1.537 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 2.902357e-02 | 1.537 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 2.925281e-02 | 1.534 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 2.943772e-02 | 1.531 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 2.943772e-02 | 1.531 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 2.943772e-02 | 1.531 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 2.943772e-02 | 1.531 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 3.075300e-02 | 1.512 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 3.075300e-02 | 1.512 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 3.098076e-02 | 1.509 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 3.098076e-02 | 1.509 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 3.225694e-02 | 1.491 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 3.351437e-02 | 1.475 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 3.797721e-02 | 1.420 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 3.544525e-02 | 1.450 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 3.466240e-02 | 1.460 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 4.224378e-02 | 1.374 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 3.469890e-02 | 1.460 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 3.842573e-02 | 1.415 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 3.769793e-02 | 1.424 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 3.469890e-02 | 1.460 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 4.104429e-02 | 1.387 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 4.224378e-02 | 1.374 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 3.469890e-02 | 1.460 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 3.778661e-02 | 1.423 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 4.002677e-02 | 1.398 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 4.256873e-02 | 1.371 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 3.631792e-02 | 1.440 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 3.778661e-02 | 1.423 | 0 | 0 |
| MTF1 activates gene expression | R-HSA-5660489 | 3.797721e-02 | 1.420 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 4.203332e-02 | 1.376 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 4.224378e-02 | 1.374 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 4.002677e-02 | 1.398 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 3.587500e-02 | 1.445 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 4.240426e-02 | 1.373 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 3.679456e-02 | 1.434 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 3.469890e-02 | 1.460 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 3.778661e-02 | 1.423 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 4.104429e-02 | 1.387 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 4.388305e-02 | 1.358 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 4.447401e-02 | 1.352 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 4.447401e-02 | 1.352 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 4.447401e-02 | 1.352 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 4.505491e-02 | 1.346 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 4.505491e-02 | 1.346 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 4.558284e-02 | 1.341 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 4.558635e-02 | 1.341 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 4.638027e-02 | 1.334 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 4.744580e-02 | 1.324 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 4.807746e-02 | 1.318 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 4.831462e-02 | 1.316 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 4.918946e-02 | 1.308 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 4.918946e-02 | 1.308 | 0 | 0 |
| Defective translocation of RB1 mutants to the nucleus | R-HSA-9661070 | 4.953084e-02 | 1.305 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 4.990449e-02 | 1.302 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 4.995113e-02 | 1.301 | 0 | 0 |
| IRS activation | R-HSA-74713 | 5.002098e-02 | 1.301 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 5.002098e-02 | 1.301 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 5.002098e-02 | 1.301 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 5.002098e-02 | 1.301 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 5.041943e-02 | 1.297 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 5.041943e-02 | 1.297 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 5.041943e-02 | 1.297 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 5.074915e-02 | 1.295 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 5.074915e-02 | 1.295 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 5.074915e-02 | 1.295 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 5.074915e-02 | 1.295 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 5.077333e-02 | 1.294 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 5.147260e-02 | 1.288 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 5.185603e-02 | 1.285 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 5.185603e-02 | 1.285 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 5.185603e-02 | 1.285 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 5.387322e-02 | 1.269 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 5.476820e-02 | 1.261 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 5.535100e-02 | 1.257 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 6.514101e-02 | 1.186 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 7.389774e-02 | 1.131 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 5.778380e-02 | 1.238 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 6.456426e-02 | 1.190 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 5.994231e-02 | 1.222 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 6.939500e-02 | 1.159 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 6.651010e-02 | 1.177 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 5.581075e-02 | 1.253 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 5.581075e-02 | 1.253 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 5.581075e-02 | 1.253 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 6.850609e-02 | 1.164 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 5.611842e-02 | 1.251 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 6.018582e-02 | 1.221 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 7.389774e-02 | 1.131 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 7.389774e-02 | 1.131 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 6.062794e-02 | 1.217 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 7.389774e-02 | 1.131 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 6.018582e-02 | 1.221 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 5.581075e-02 | 1.253 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 6.526456e-02 | 1.185 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 7.243733e-02 | 1.140 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 7.055145e-02 | 1.151 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 6.141778e-02 | 1.212 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 7.338576e-02 | 1.134 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 6.873709e-02 | 1.163 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 7.338576e-02 | 1.134 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 7.389774e-02 | 1.131 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 6.123995e-02 | 1.213 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 5.689811e-02 | 1.245 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 7.389774e-02 | 1.131 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 5.778380e-02 | 1.238 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 6.925384e-02 | 1.160 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 6.651010e-02 | 1.177 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 6.914982e-02 | 1.160 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 6.214874e-02 | 1.207 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 7.280554e-02 | 1.138 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 6.494240e-02 | 1.187 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 6.287850e-02 | 1.201 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 5.696558e-02 | 1.244 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 7.499307e-02 | 1.125 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 7.518512e-02 | 1.124 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 7.556742e-02 | 1.122 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 7.562414e-02 | 1.121 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 7.607937e-02 | 1.119 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 7.607937e-02 | 1.119 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 7.607937e-02 | 1.119 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 7.699405e-02 | 1.114 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 7.746495e-02 | 1.111 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 7.746495e-02 | 1.111 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 7.746495e-02 | 1.111 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 7.766024e-02 | 1.110 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 7.823930e-02 | 1.107 | 0 | 0 |
| Depurination | R-HSA-73927 | 8.183452e-02 | 1.087 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 8.217948e-02 | 1.085 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 8.314602e-02 | 1.080 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 8.314602e-02 | 1.080 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 8.314602e-02 | 1.080 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 8.359268e-02 | 1.078 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 8.474676e-02 | 1.072 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 8.580788e-02 | 1.066 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 8.781413e-02 | 1.056 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 8.844269e-02 | 1.053 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 8.850200e-02 | 1.053 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 8.948192e-02 | 1.048 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 9.258687e-02 | 1.033 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 9.258687e-02 | 1.033 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 9.258687e-02 | 1.033 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 9.258687e-02 | 1.033 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 9.286211e-02 | 1.032 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 9.286211e-02 | 1.032 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 9.661123e-02 | 1.015 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 9.661123e-02 | 1.015 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 9.661123e-02 | 1.015 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 9.661123e-02 | 1.015 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 9.661123e-02 | 1.015 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 9.661123e-02 | 1.015 | 0 | 0 |
| Formation of editosomes by ADAR proteins | R-HSA-77042 | 9.661123e-02 | 1.015 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 9.661123e-02 | 1.015 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 9.708435e-02 | 1.013 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 9.793138e-02 | 1.009 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 9.933613e-02 | 1.003 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 1.004333e-01 | 0.998 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 1.011541e-01 | 0.995 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 1.030211e-01 | 0.987 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 1.030211e-01 | 0.987 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 1.030211e-01 | 0.987 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 1.030211e-01 | 0.987 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 1.047897e-01 | 0.980 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 1.049780e-01 | 0.979 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 1.050368e-01 | 0.979 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 1.055854e-01 | 0.976 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 1.057020e-01 | 0.976 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 1.057020e-01 | 0.976 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 1.057020e-01 | 0.976 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 1.062710e-01 | 0.974 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 1.070649e-01 | 0.970 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 1.084749e-01 | 0.965 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 1.084749e-01 | 0.965 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 1.084749e-01 | 0.965 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 1.084749e-01 | 0.965 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 1.084749e-01 | 0.965 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 1.084749e-01 | 0.965 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 1.084749e-01 | 0.965 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 1.084749e-01 | 0.965 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 1.109038e-01 | 0.955 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 1.115244e-01 | 0.953 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 1.116344e-01 | 0.952 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 1.125112e-01 | 0.949 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 1.127464e-01 | 0.948 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 1.131532e-01 | 0.946 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 1.135139e-01 | 0.945 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 1.135974e-01 | 0.945 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 1.135974e-01 | 0.945 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 1.135974e-01 | 0.945 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 1.139052e-01 | 0.943 | 0 | 0 |
| Defective VWF binding to collagen type I | R-HSA-9845622 | 1.413623e-01 | 0.850 | 0 | 0 |
| Defective PGM1 causes PGM1-CDG | R-HSA-5609974 | 1.413623e-01 | 0.850 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 1.413623e-01 | 0.850 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 1.250163e-01 | 0.903 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 1.596537e-01 | 0.797 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 1.595426e-01 | 0.797 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 1.216000e-01 | 0.915 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 1.718047e-01 | 0.765 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 1.675197e-01 | 0.776 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 1.519602e-01 | 0.818 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 1.250163e-01 | 0.903 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 1.294742e-01 | 0.888 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 1.646209e-01 | 0.784 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 1.245644e-01 | 0.905 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 1.151532e-01 | 0.939 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 1.413623e-01 | 0.850 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 1.250163e-01 | 0.903 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 1.250163e-01 | 0.903 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 1.595426e-01 | 0.797 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 1.671740e-01 | 0.777 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 1.675197e-01 | 0.776 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 1.421075e-01 | 0.847 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 1.421075e-01 | 0.847 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 1.421075e-01 | 0.847 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 1.718047e-01 | 0.765 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 1.718047e-01 | 0.765 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 1.665600e-01 | 0.778 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 1.611588e-01 | 0.793 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 1.194973e-01 | 0.923 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 1.421075e-01 | 0.847 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 1.294742e-01 | 0.888 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 1.294742e-01 | 0.888 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 1.590297e-01 | 0.799 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 1.397748e-01 | 0.855 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 1.250163e-01 | 0.903 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 1.596537e-01 | 0.797 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 1.646209e-01 | 0.784 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 1.595426e-01 | 0.797 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 1.173590e-01 | 0.930 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 1.426304e-01 | 0.846 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 1.519602e-01 | 0.818 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 1.645280e-01 | 0.784 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 1.596537e-01 | 0.797 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 1.596537e-01 | 0.797 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 1.595426e-01 | 0.797 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 1.392652e-01 | 0.856 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 1.475640e-01 | 0.831 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 1.421075e-01 | 0.847 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 1.494306e-01 | 0.826 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 1.838990e-01 | 0.735 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 1.838990e-01 | 0.735 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 1.838990e-01 | 0.735 | 0 | 0 |
| Defective ALG9 causes CDG-1l | R-HSA-4720454 | 1.838990e-01 | 0.735 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 1.838990e-01 | 0.735 | 0 | 0 |
| Defective SLC6A5 causes hyperekplexia 3 (HKPX3) | R-HSA-5619089 | 1.838990e-01 | 0.735 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 1.838990e-01 | 0.735 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 1.838990e-01 | 0.735 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 1.838990e-01 | 0.735 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 1.838990e-01 | 0.735 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 1.838990e-01 | 0.735 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 1.838990e-01 | 0.735 | 0 | 0 |
| Defective VWF cleavage by ADAMTS13 variant | R-HSA-9845621 | 1.838990e-01 | 0.735 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 1.838990e-01 | 0.735 | 0 | 0 |
| Enhanced cleavage of VWF variant by ADAMTS13 | R-HSA-9845619 | 1.838990e-01 | 0.735 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 1.838990e-01 | 0.735 | 0 | 0 |
| Signaling by RAS GAP mutants | R-HSA-9753510 | 1.838990e-01 | 0.735 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 2.243310e-01 | 0.649 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 2.243310e-01 | 0.649 | 0 | 0 |
| HCN channels | R-HSA-1296061 | 2.627622e-01 | 0.580 | 0 | 0 |
| Drug-mediated inhibition of CDK4/CDK6 activity | R-HSA-9754119 | 2.627622e-01 | 0.580 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 2.627622e-01 | 0.580 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 2.627622e-01 | 0.580 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 2.627622e-01 | 0.580 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 2.992914e-01 | 0.524 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 2.992914e-01 | 0.524 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 2.992914e-01 | 0.524 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 1.775679e-01 | 0.751 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 1.957710e-01 | 0.708 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 1.957710e-01 | 0.708 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 1.957710e-01 | 0.708 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 3.340128e-01 | 0.476 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 3.340128e-01 | 0.476 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 3.340128e-01 | 0.476 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 3.340128e-01 | 0.476 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 3.340128e-01 | 0.476 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 3.340128e-01 | 0.476 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 2.141903e-01 | 0.669 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 2.141903e-01 | 0.669 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 2.141903e-01 | 0.669 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 2.141903e-01 | 0.669 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 2.141903e-01 | 0.669 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 2.141903e-01 | 0.669 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 2.141903e-01 | 0.669 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 2.327599e-01 | 0.633 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 2.327599e-01 | 0.633 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 2.514199e-01 | 0.600 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 2.514199e-01 | 0.600 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 1.843237e-01 | 0.734 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 1.970736e-01 | 0.705 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 1.970736e-01 | 0.705 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 2.701157e-01 | 0.568 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 2.231642e-01 | 0.651 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 2.364554e-01 | 0.626 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 2.364554e-01 | 0.626 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 2.364554e-01 | 0.626 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 3.074228e-01 | 0.512 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 3.074228e-01 | 0.512 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 2.498789e-01 | 0.602 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 2.498789e-01 | 0.602 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 3.259495e-01 | 0.487 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 2.634117e-01 | 0.579 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 2.634117e-01 | 0.579 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 2.770317e-01 | 0.557 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 2.770317e-01 | 0.557 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 3.443423e-01 | 0.463 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 2.907178e-01 | 0.537 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 3.044496e-01 | 0.516 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 3.147248e-01 | 0.502 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 1.912737e-01 | 0.718 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 1.844342e-01 | 0.734 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 3.004366e-01 | 0.522 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 2.399303e-01 | 0.620 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 3.035480e-01 | 0.518 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 3.259495e-01 | 0.487 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 3.443423e-01 | 0.463 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 2.327599e-01 | 0.633 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 2.514199e-01 | 0.600 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 2.562307e-01 | 0.591 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 3.293252e-01 | 0.482 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 2.729271e-01 | 0.564 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 2.729271e-01 | 0.564 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 2.627622e-01 | 0.580 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 1.775679e-01 | 0.751 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 1.957710e-01 | 0.708 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 1.957710e-01 | 0.708 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 2.364554e-01 | 0.626 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 2.753097e-01 | 0.560 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 2.408240e-01 | 0.618 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 2.408240e-01 | 0.618 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 1.775679e-01 | 0.751 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 3.339844e-01 | 0.476 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 2.860170e-01 | 0.544 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 1.960273e-01 | 0.708 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 2.326744e-01 | 0.633 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 2.992914e-01 | 0.524 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 2.992914e-01 | 0.524 | 0 | 0 |
| PTK6 Down-Regulation | R-HSA-8849472 | 2.992914e-01 | 0.524 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 1.957710e-01 | 0.708 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 3.259495e-01 | 0.487 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 2.184828e-01 | 0.661 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 2.374924e-01 | 0.624 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 2.514199e-01 | 0.600 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 3.259495e-01 | 0.487 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 3.313040e-01 | 0.480 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 2.992914e-01 | 0.524 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 3.340128e-01 | 0.476 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 2.364554e-01 | 0.626 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 2.562307e-01 | 0.591 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 3.044334e-01 | 0.517 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 2.508315e-01 | 0.601 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 1.873866e-01 | 0.727 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 2.840975e-01 | 0.547 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 2.498789e-01 | 0.602 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 3.182076e-01 | 0.497 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 2.798982e-01 | 0.553 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 3.142460e-01 | 0.503 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 3.035480e-01 | 0.518 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 2.140535e-01 | 0.669 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 3.044334e-01 | 0.517 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 2.796904e-01 | 0.553 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 2.796904e-01 | 0.553 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 2.796904e-01 | 0.553 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 2.399303e-01 | 0.620 | 0 | 0 |
| mRNA Editing: A to I Conversion | R-HSA-75064 | 1.838990e-01 | 0.735 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 1.838990e-01 | 0.735 | 0 | 0 |
| C6 deamination of adenosine | R-HSA-75102 | 1.838990e-01 | 0.735 | 0 | 0 |
| NTRK2 activates RAC1 | R-HSA-9032759 | 2.992914e-01 | 0.524 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 2.701157e-01 | 0.568 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 2.364554e-01 | 0.626 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 3.074228e-01 | 0.512 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 2.498789e-01 | 0.602 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 3.259495e-01 | 0.487 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 1.925414e-01 | 0.715 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 3.407133e-01 | 0.468 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 2.798982e-01 | 0.553 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 2.953338e-01 | 0.530 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 2.291433e-01 | 0.640 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 3.402127e-01 | 0.468 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 2.012844e-01 | 0.696 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 2.327599e-01 | 0.633 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 2.887982e-01 | 0.539 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 2.498789e-01 | 0.602 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 2.634117e-01 | 0.579 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 2.307570e-01 | 0.637 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 2.907178e-01 | 0.537 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 1.775679e-01 | 0.751 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 1.957710e-01 | 0.708 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 3.340128e-01 | 0.476 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 3.340128e-01 | 0.476 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 2.887982e-01 | 0.539 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 1.839371e-01 | 0.735 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 3.182076e-01 | 0.497 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 3.182076e-01 | 0.497 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 3.319731e-01 | 0.479 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 2.100288e-01 | 0.678 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 2.753097e-01 | 0.560 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 3.179587e-01 | 0.498 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 2.327599e-01 | 0.633 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 2.802962e-01 | 0.552 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 1.970736e-01 | 0.705 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 1.901553e-01 | 0.721 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 1.831852e-01 | 0.737 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 2.618345e-01 | 0.582 | 0 | 0 |
| Sensory perception of sour taste | R-HSA-9729555 | 2.627622e-01 | 0.580 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 1.775679e-01 | 0.751 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 1.775679e-01 | 0.751 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 3.340128e-01 | 0.476 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 2.141903e-01 | 0.669 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 3.443423e-01 | 0.463 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 2.291697e-01 | 0.640 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 3.247417e-01 | 0.488 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 3.159402e-01 | 0.500 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 2.243310e-01 | 0.649 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 2.887982e-01 | 0.539 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 1.873866e-01 | 0.727 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 2.950812e-01 | 0.530 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 2.116063e-01 | 0.674 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 2.282703e-01 | 0.642 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 2.840975e-01 | 0.547 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 2.840975e-01 | 0.547 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 1.857683e-01 | 0.731 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 2.734059e-01 | 0.563 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 2.408240e-01 | 0.618 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 2.265259e-01 | 0.645 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 2.701157e-01 | 0.568 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 1.773584e-01 | 0.751 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 1.873866e-01 | 0.727 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 1.909255e-01 | 0.719 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 3.142460e-01 | 0.503 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 2.770317e-01 | 0.557 | 0 | 0 |
| Disease | R-HSA-1643685 | 2.164607e-01 | 0.665 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 3.262360e-01 | 0.486 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 2.849578e-01 | 0.545 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 2.141903e-01 | 0.669 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 3.319731e-01 | 0.479 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 2.618345e-01 | 0.582 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 2.840975e-01 | 0.547 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 1.970736e-01 | 0.705 | 0 | 0 |
| FasL/ CD95L signaling | R-HSA-75157 | 2.243310e-01 | 0.649 | 0 | 0 |
| Maturation of protein E | R-HSA-9694493 | 3.340128e-01 | 0.476 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 3.340128e-01 | 0.476 | 0 | 0 |
| Maturation of protein E | R-HSA-9683683 | 3.340128e-01 | 0.476 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 1.843237e-01 | 0.734 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 3.195349e-01 | 0.495 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 1.854885e-01 | 0.732 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 2.327149e-01 | 0.633 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 2.416278e-01 | 0.617 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 3.004366e-01 | 0.522 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 1.873866e-01 | 0.727 | 0 | 0 |
| TRAIL signaling | R-HSA-75158 | 3.340128e-01 | 0.476 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 2.618345e-01 | 0.582 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 3.319731e-01 | 0.479 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 2.831035e-01 | 0.548 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 2.408846e-01 | 0.618 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 1.775679e-01 | 0.751 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 3.340128e-01 | 0.476 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 3.259495e-01 | 0.487 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 3.443423e-01 | 0.463 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 1.930802e-01 | 0.714 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 3.182076e-01 | 0.497 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 1.970736e-01 | 0.705 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 1.970736e-01 | 0.705 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 3.091774e-01 | 0.510 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 2.364554e-01 | 0.626 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 1.773584e-01 | 0.751 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 2.364554e-01 | 0.626 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 2.282703e-01 | 0.642 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 2.701157e-01 | 0.568 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 2.364554e-01 | 0.626 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 3.179587e-01 | 0.498 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 2.327599e-01 | 0.633 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 1.843237e-01 | 0.734 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 3.259495e-01 | 0.487 | 0 | 0 |
| Response to metal ions | R-HSA-5660526 | 2.887982e-01 | 0.539 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 3.457286e-01 | 0.461 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 3.457286e-01 | 0.461 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 3.457286e-01 | 0.461 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 3.457286e-01 | 0.461 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 3.457286e-01 | 0.461 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 3.497510e-01 | 0.456 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 3.521127e-01 | 0.453 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 3.594573e-01 | 0.444 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 3.594573e-01 | 0.444 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 3.594573e-01 | 0.444 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 3.625690e-01 | 0.441 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 3.625690e-01 | 0.441 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 3.625690e-01 | 0.441 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 3.625690e-01 | 0.441 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 3.625690e-01 | 0.441 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 3.625690e-01 | 0.441 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 3.625690e-01 | 0.441 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 3.625690e-01 | 0.441 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 3.635135e-01 | 0.439 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 3.637687e-01 | 0.439 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 3.670157e-01 | 0.435 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 3.670157e-01 | 0.435 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 3.670157e-01 | 0.435 | 0 | 0 |
| Branched-chain ketoacid dehydrogenase kinase deficiency | R-HSA-9912481 | 3.670157e-01 | 0.435 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 3.670157e-01 | 0.435 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 3.670157e-01 | 0.435 | 0 | 0 |
| NADPH regeneration | R-HSA-389542 | 3.670157e-01 | 0.435 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 3.687347e-01 | 0.433 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 3.731431e-01 | 0.428 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 3.731431e-01 | 0.428 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 3.731431e-01 | 0.428 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 3.731431e-01 | 0.428 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 3.732044e-01 | 0.428 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 3.737167e-01 | 0.427 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 3.737167e-01 | 0.427 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 3.749058e-01 | 0.426 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 3.749058e-01 | 0.426 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 3.806011e-01 | 0.420 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 3.806011e-01 | 0.420 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 3.806011e-01 | 0.420 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 3.806011e-01 | 0.420 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 3.806011e-01 | 0.420 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 3.806011e-01 | 0.420 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 3.845671e-01 | 0.415 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 3.867712e-01 | 0.413 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 3.867712e-01 | 0.413 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 3.920834e-01 | 0.407 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 3.951988e-01 | 0.403 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 3.976283e-01 | 0.401 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 3.976283e-01 | 0.401 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 3.980816e-01 | 0.400 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 3.983851e-01 | 0.400 | 0 | 0 |
| Progressive trimming of alpha-1,2-linked mannose residues from Man9/8/7GlcNAc2 to produce Man5GlcNAc2 | R-HSA-964827 | 3.983851e-01 | 0.400 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 3.983851e-01 | 0.400 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 3.983851e-01 | 0.400 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 3.983851e-01 | 0.400 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 3.983851e-01 | 0.400 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 3.983851e-01 | 0.400 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 3.983851e-01 | 0.400 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 3.983851e-01 | 0.400 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 3.983851e-01 | 0.400 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 3.983851e-01 | 0.400 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 3.983851e-01 | 0.400 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 3.984129e-01 | 0.400 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 3.984129e-01 | 0.400 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 3.984129e-01 | 0.400 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 3.984129e-01 | 0.400 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 3.984129e-01 | 0.400 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 4.035294e-01 | 0.394 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 4.035294e-01 | 0.394 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 4.035294e-01 | 0.394 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 4.089407e-01 | 0.388 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 4.089407e-01 | 0.388 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 4.089407e-01 | 0.388 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 4.089407e-01 | 0.388 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 4.137983e-01 | 0.383 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 4.137983e-01 | 0.383 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 4.137983e-01 | 0.383 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 4.137983e-01 | 0.383 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 4.137983e-01 | 0.383 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 4.137983e-01 | 0.383 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 4.137983e-01 | 0.383 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 4.137983e-01 | 0.383 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 4.159343e-01 | 0.381 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 4.159823e-01 | 0.381 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 4.159823e-01 | 0.381 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 4.159823e-01 | 0.381 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 4.159823e-01 | 0.381 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 4.179994e-01 | 0.379 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 4.254828e-01 | 0.371 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 4.271717e-01 | 0.369 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 4.271717e-01 | 0.369 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 4.271717e-01 | 0.369 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 4.271717e-01 | 0.369 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 4.271717e-01 | 0.369 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 4.282016e-01 | 0.368 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 4.282016e-01 | 0.368 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 4.282016e-01 | 0.368 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 4.282016e-01 | 0.368 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 4.282016e-01 | 0.368 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 4.282016e-01 | 0.368 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 4.282016e-01 | 0.368 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 4.282016e-01 | 0.368 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 4.282016e-01 | 0.368 | 0 | 0 |
| SLC-mediated bile acid transport | R-HSA-9958517 | 4.282016e-01 | 0.368 | 0 | 0 |
| RSK activation | R-HSA-444257 | 4.282016e-01 | 0.368 | 0 | 0 |
| Modulation by Mtb of host immune system | R-HSA-9637628 | 4.282016e-01 | 0.368 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 4.331764e-01 | 0.363 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 4.332893e-01 | 0.363 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 4.332893e-01 | 0.363 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 4.404357e-01 | 0.356 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 4.404357e-01 | 0.356 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 4.404357e-01 | 0.356 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 4.404357e-01 | 0.356 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 4.503170e-01 | 0.346 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 4.503170e-01 | 0.346 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 4.535797e-01 | 0.343 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 4.535797e-01 | 0.343 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 4.535797e-01 | 0.343 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 4.535797e-01 | 0.343 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 4.535797e-01 | 0.343 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 4.535797e-01 | 0.343 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 4.558528e-01 | 0.341 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 4.565421e-01 | 0.341 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 4.565421e-01 | 0.341 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 4.565421e-01 | 0.341 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 4.565421e-01 | 0.341 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 4.565421e-01 | 0.341 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 4.565421e-01 | 0.341 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 4.565421e-01 | 0.341 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 4.565421e-01 | 0.341 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 4.565421e-01 | 0.341 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 4.565421e-01 | 0.341 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 4.602248e-01 | 0.337 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 4.646928e-01 | 0.333 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 4.670506e-01 | 0.331 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 4.670506e-01 | 0.331 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 4.670506e-01 | 0.331 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 4.689921e-01 | 0.329 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 4.689921e-01 | 0.329 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 4.689921e-01 | 0.329 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 4.708812e-01 | 0.327 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 4.756305e-01 | 0.323 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 4.756305e-01 | 0.323 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 4.768415e-01 | 0.322 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 4.771386e-01 | 0.321 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 4.794682e-01 | 0.319 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 4.819580e-01 | 0.317 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 4.834773e-01 | 0.316 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 4.834773e-01 | 0.316 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 4.834773e-01 | 0.316 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 4.834773e-01 | 0.316 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 4.834773e-01 | 0.316 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 4.834773e-01 | 0.316 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 4.834796e-01 | 0.316 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 4.834796e-01 | 0.316 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 4.834796e-01 | 0.316 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 4.834796e-01 | 0.316 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 4.834796e-01 | 0.316 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 4.834796e-01 | 0.316 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 4.834796e-01 | 0.316 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 4.834796e-01 | 0.316 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 4.834796e-01 | 0.316 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 4.834796e-01 | 0.316 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 4.864820e-01 | 0.313 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 4.921949e-01 | 0.308 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 4.921949e-01 | 0.308 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 4.921949e-01 | 0.308 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 4.930889e-01 | 0.307 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 4.950454e-01 | 0.305 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 4.980710e-01 | 0.303 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 4.995864e-01 | 0.301 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 4.995864e-01 | 0.301 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 5.036355e-01 | 0.298 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 5.036355e-01 | 0.298 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 5.047659e-01 | 0.297 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 5.047659e-01 | 0.297 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 5.047659e-01 | 0.297 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 5.059763e-01 | 0.296 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 5.090835e-01 | 0.293 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 5.090835e-01 | 0.293 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 5.153693e-01 | 0.288 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 5.153693e-01 | 0.288 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 5.153693e-01 | 0.288 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 5.171740e-01 | 0.286 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 5.171740e-01 | 0.286 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 5.171740e-01 | 0.286 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 5.171740e-01 | 0.286 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 5.195978e-01 | 0.284 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 5.288719e-01 | 0.277 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 5.290786e-01 | 0.276 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 5.290786e-01 | 0.276 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 5.294127e-01 | 0.276 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 5.294127e-01 | 0.276 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 5.294307e-01 | 0.276 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 5.308185e-01 | 0.275 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 5.308185e-01 | 0.275 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 5.308185e-01 | 0.275 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 5.334196e-01 | 0.273 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 5.334196e-01 | 0.273 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 5.334196e-01 | 0.273 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 5.334196e-01 | 0.273 | 0 | 0 |
| Plasmalogen biosynthesis | R-HSA-75896 | 5.334196e-01 | 0.273 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 5.334196e-01 | 0.273 | 0 | 0 |
| Viral RNP Complexes in the Host Cell Nucleus | R-HSA-168330 | 5.334196e-01 | 0.273 | 0 | 0 |
| Anchoring fibril formation | R-HSA-2214320 | 5.334196e-01 | 0.273 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 5.334196e-01 | 0.273 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 5.380658e-01 | 0.269 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 5.392535e-01 | 0.268 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 5.459284e-01 | 0.263 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 5.459284e-01 | 0.263 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 5.459284e-01 | 0.263 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 5.459284e-01 | 0.263 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 5.533594e-01 | 0.257 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 5.533594e-01 | 0.257 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 5.565507e-01 | 0.254 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 5.565507e-01 | 0.254 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 5.565507e-01 | 0.254 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 5.565507e-01 | 0.254 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 5.565507e-01 | 0.254 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 5.565507e-01 | 0.254 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 5.565507e-01 | 0.254 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 5.565507e-01 | 0.254 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 5.565507e-01 | 0.254 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 5.565507e-01 | 0.254 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 5.565507e-01 | 0.254 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 5.565507e-01 | 0.254 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 5.565507e-01 | 0.254 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 5.565507e-01 | 0.254 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 5.565507e-01 | 0.254 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 5.593033e-01 | 0.252 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 5.595796e-01 | 0.252 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 5.595796e-01 | 0.252 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 5.606946e-01 | 0.251 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 5.606946e-01 | 0.251 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 5.621328e-01 | 0.250 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 5.651342e-01 | 0.248 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 5.678285e-01 | 0.246 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 5.695587e-01 | 0.244 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 5.695587e-01 | 0.244 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 5.751142e-01 | 0.240 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 5.751142e-01 | 0.240 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 5.751142e-01 | 0.240 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 5.765661e-01 | 0.239 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 5.765661e-01 | 0.239 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 5.765661e-01 | 0.239 | 0 | 0 |
| Reversible hydration of carbon dioxide | R-HSA-1475029 | 5.785364e-01 | 0.238 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 5.785364e-01 | 0.238 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 5.785364e-01 | 0.238 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 5.785364e-01 | 0.238 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 5.794106e-01 | 0.237 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 5.794106e-01 | 0.237 | 0 | 0 |
| Immune System | R-HSA-168256 | 5.831844e-01 | 0.234 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 5.878820e-01 | 0.231 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 5.878820e-01 | 0.231 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 5.878820e-01 | 0.231 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 5.878820e-01 | 0.231 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 5.891852e-01 | 0.230 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 5.891852e-01 | 0.230 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 5.891852e-01 | 0.230 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 5.891852e-01 | 0.230 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 5.891852e-01 | 0.230 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 5.891852e-01 | 0.230 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 5.891852e-01 | 0.230 | 0 | 0 |
| Protein folding | R-HSA-391251 | 5.913722e-01 | 0.228 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 5.987213e-01 | 0.223 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 5.990020e-01 | 0.223 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 5.990020e-01 | 0.223 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 5.990020e-01 | 0.223 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 5.994334e-01 | 0.222 | 0 | 0 |
| N-glycan trimming and elongation in the cis-Golgi | R-HSA-964739 | 5.994334e-01 | 0.222 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 5.994334e-01 | 0.222 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 5.994334e-01 | 0.222 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 5.994334e-01 | 0.222 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 5.994334e-01 | 0.222 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 5.994334e-01 | 0.222 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 5.994334e-01 | 0.222 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 5.994334e-01 | 0.222 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 6.018319e-01 | 0.221 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 6.029067e-01 | 0.220 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 6.029067e-01 | 0.220 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 6.029067e-01 | 0.220 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 6.029067e-01 | 0.220 | 0 | 0 |
| Glutamate and glutamine metabolism | R-HSA-8964539 | 6.029067e-01 | 0.220 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 6.058915e-01 | 0.218 | 0 | 0 |
| S Phase | R-HSA-69242 | 6.065837e-01 | 0.217 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 6.081747e-01 | 0.216 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 6.081747e-01 | 0.216 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 6.083698e-01 | 0.216 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 6.099235e-01 | 0.215 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 6.162787e-01 | 0.210 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 6.162787e-01 | 0.210 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 6.162787e-01 | 0.210 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 6.171557e-01 | 0.210 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 6.171557e-01 | 0.210 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 6.182871e-01 | 0.209 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 6.192954e-01 | 0.208 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 6.192954e-01 | 0.208 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 6.192954e-01 | 0.208 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 6.192954e-01 | 0.208 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 6.192954e-01 | 0.208 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 6.192954e-01 | 0.208 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 6.192954e-01 | 0.208 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 6.192954e-01 | 0.208 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 6.192954e-01 | 0.208 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 6.192954e-01 | 0.208 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 6.206442e-01 | 0.207 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 6.266668e-01 | 0.203 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 6.293022e-01 | 0.201 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 6.293022e-01 | 0.201 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 6.311626e-01 | 0.200 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 6.367803e-01 | 0.196 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 6.381738e-01 | 0.195 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 6.381738e-01 | 0.195 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 6.381738e-01 | 0.195 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 6.381738e-01 | 0.195 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 6.381738e-01 | 0.195 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 6.381738e-01 | 0.195 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 6.381738e-01 | 0.195 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 6.381738e-01 | 0.195 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 6.381738e-01 | 0.195 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 6.381738e-01 | 0.195 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 6.381738e-01 | 0.195 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 6.381738e-01 | 0.195 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 6.392545e-01 | 0.194 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 6.392545e-01 | 0.194 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 6.419789e-01 | 0.192 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 6.419789e-01 | 0.192 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 6.515871e-01 | 0.186 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 6.561170e-01 | 0.183 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 6.561170e-01 | 0.183 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 6.561170e-01 | 0.183 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 6.561170e-01 | 0.183 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 6.561170e-01 | 0.183 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 6.561170e-01 | 0.183 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 6.561170e-01 | 0.183 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 6.561170e-01 | 0.183 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 6.561170e-01 | 0.183 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 6.561170e-01 | 0.183 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 6.561170e-01 | 0.183 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | R-HSA-400511 | 6.561170e-01 | 0.183 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 6.561170e-01 | 0.183 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 6.619444e-01 | 0.179 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 6.631461e-01 | 0.178 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 6.659611e-01 | 0.177 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 6.659611e-01 | 0.177 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 6.663018e-01 | 0.176 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 6.663018e-01 | 0.176 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 6.663018e-01 | 0.176 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 6.720980e-01 | 0.173 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 6.731715e-01 | 0.172 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 6.731715e-01 | 0.172 | 0 | 0 |
| GDP-fucose biosynthesis | R-HSA-6787639 | 6.731715e-01 | 0.172 | 0 | 0 |
| Choline catabolism | R-HSA-6798163 | 6.731715e-01 | 0.172 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 6.731715e-01 | 0.172 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 6.731715e-01 | 0.172 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 6.731715e-01 | 0.172 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 6.731715e-01 | 0.172 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 6.763686e-01 | 0.170 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 6.779546e-01 | 0.169 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 6.779546e-01 | 0.169 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 6.779546e-01 | 0.169 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 6.806843e-01 | 0.167 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 6.892733e-01 | 0.162 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 6.892733e-01 | 0.162 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 6.892733e-01 | 0.162 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 6.892733e-01 | 0.162 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 6.892733e-01 | 0.162 | 0 | 0 |
| Organic anion transport by SLC5/17/25 transporters | R-HSA-428643 | 6.893812e-01 | 0.162 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 6.893812e-01 | 0.162 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 6.899727e-01 | 0.161 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 6.899727e-01 | 0.161 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 6.904229e-01 | 0.161 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 7.002626e-01 | 0.155 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 7.027041e-01 | 0.153 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 7.047879e-01 | 0.152 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 7.047879e-01 | 0.152 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 7.047879e-01 | 0.152 | 0 | 0 |
| Crosslinking of collagen fibrils | R-HSA-2243919 | 7.047879e-01 | 0.152 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 7.047879e-01 | 0.152 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 7.047879e-01 | 0.152 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 7.047879e-01 | 0.152 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 7.047879e-01 | 0.152 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 7.047879e-01 | 0.152 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 7.047879e-01 | 0.152 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 7.047879e-01 | 0.152 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 7.047879e-01 | 0.152 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 7.047879e-01 | 0.152 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 7.047879e-01 | 0.152 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 7.079371e-01 | 0.150 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 7.104775e-01 | 0.148 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 7.104775e-01 | 0.148 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 7.194313e-01 | 0.143 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 7.194313e-01 | 0.143 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 7.194313e-01 | 0.143 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 7.194313e-01 | 0.143 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 7.194313e-01 | 0.143 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 7.194313e-01 | 0.143 | 0 | 0 |
| Wax and plasmalogen biosynthesis | R-HSA-8848584 | 7.194313e-01 | 0.143 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 7.220523e-01 | 0.141 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 7.285721e-01 | 0.138 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 7.285721e-01 | 0.138 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 7.313034e-01 | 0.136 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 7.327558e-01 | 0.135 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 7.333491e-01 | 0.135 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 7.333491e-01 | 0.135 | 0 | 0 |
| Prevention of phagosomal-lysosomal fusion | R-HSA-9636383 | 7.333491e-01 | 0.135 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 7.333491e-01 | 0.135 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 7.333491e-01 | 0.135 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 7.333491e-01 | 0.135 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 7.333491e-01 | 0.135 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 7.333694e-01 | 0.135 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 7.410261e-01 | 0.130 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 7.410261e-01 | 0.130 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 7.414490e-01 | 0.130 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 7.432045e-01 | 0.129 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 7.465774e-01 | 0.127 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 7.465774e-01 | 0.127 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 7.465774e-01 | 0.127 | 0 | 0 |
| Molybdenum cofactor biosynthesis | R-HSA-947581 | 7.465774e-01 | 0.127 | 0 | 0 |
| Serine metabolism | R-HSA-977347 | 7.465774e-01 | 0.127 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 7.488362e-01 | 0.126 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 7.504463e-01 | 0.125 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 7.537217e-01 | 0.123 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 7.540409e-01 | 0.123 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 7.541706e-01 | 0.123 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 7.570230e-01 | 0.121 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 7.570230e-01 | 0.121 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 7.570230e-01 | 0.121 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 7.591502e-01 | 0.120 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 7.591502e-01 | 0.120 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 7.591502e-01 | 0.120 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 7.591502e-01 | 0.120 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 7.591502e-01 | 0.120 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 7.591502e-01 | 0.120 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 7.594234e-01 | 0.120 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 7.595700e-01 | 0.119 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 7.595700e-01 | 0.119 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 7.595700e-01 | 0.119 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 7.604225e-01 | 0.119 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 7.710999e-01 | 0.113 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 7.710999e-01 | 0.113 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 7.710999e-01 | 0.113 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 7.710999e-01 | 0.113 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 7.710999e-01 | 0.113 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 7.710999e-01 | 0.113 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 7.710999e-01 | 0.113 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 7.718311e-01 | 0.112 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 7.769533e-01 | 0.110 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 7.796759e-01 | 0.108 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 7.824575e-01 | 0.107 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 7.824575e-01 | 0.107 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 7.824575e-01 | 0.107 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 7.824575e-01 | 0.107 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 7.824575e-01 | 0.107 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 7.824575e-01 | 0.107 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 7.824575e-01 | 0.107 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 7.824575e-01 | 0.107 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 7.834544e-01 | 0.106 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 7.892405e-01 | 0.103 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 7.926504e-01 | 0.101 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 7.932268e-01 | 0.101 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 7.932521e-01 | 0.101 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 7.932521e-01 | 0.101 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 7.932521e-01 | 0.101 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 7.932521e-01 | 0.101 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 7.932521e-01 | 0.101 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 7.932521e-01 | 0.101 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 7.957490e-01 | 0.099 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 7.985393e-01 | 0.098 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 7.985393e-01 | 0.098 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 8.035118e-01 | 0.095 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 8.035118e-01 | 0.095 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 8.035118e-01 | 0.095 | 0 | 0 |
| Diseases of branched-chain amino acid catabolism | R-HSA-9865118 | 8.035118e-01 | 0.095 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 8.084423e-01 | 0.092 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 8.100742e-01 | 0.091 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 8.118632e-01 | 0.091 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 8.132629e-01 | 0.090 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 8.132629e-01 | 0.090 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 8.132629e-01 | 0.090 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 8.132629e-01 | 0.090 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 8.132629e-01 | 0.090 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 8.147937e-01 | 0.089 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 8.225307e-01 | 0.085 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 8.225307e-01 | 0.085 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 8.225307e-01 | 0.085 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 8.291050e-01 | 0.081 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 8.313390e-01 | 0.080 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 8.313390e-01 | 0.080 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 8.313390e-01 | 0.080 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 8.313390e-01 | 0.080 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 8.313390e-01 | 0.080 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 8.313390e-01 | 0.080 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 8.313390e-01 | 0.080 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 8.397107e-01 | 0.076 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 8.397107e-01 | 0.076 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 8.397107e-01 | 0.076 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 8.397107e-01 | 0.076 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 8.397107e-01 | 0.076 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 8.405306e-01 | 0.075 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 8.421951e-01 | 0.075 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 8.446540e-01 | 0.073 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 8.476673e-01 | 0.072 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 8.476673e-01 | 0.072 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 8.505122e-01 | 0.070 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 8.508957e-01 | 0.070 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 8.531962e-01 | 0.069 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 8.541169e-01 | 0.068 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 8.558547e-01 | 0.068 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 8.597645e-01 | 0.066 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 8.597645e-01 | 0.066 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 8.597645e-01 | 0.066 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 8.614757e-01 | 0.065 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 8.616957e-01 | 0.065 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 8.624165e-01 | 0.064 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 8.624165e-01 | 0.064 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 8.624165e-01 | 0.064 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 8.624165e-01 | 0.064 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 8.652115e-01 | 0.063 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 8.665370e-01 | 0.062 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 8.665370e-01 | 0.062 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 8.692473e-01 | 0.061 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 8.704637e-01 | 0.060 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 8.721792e-01 | 0.059 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 8.757393e-01 | 0.058 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 8.757393e-01 | 0.058 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 8.757393e-01 | 0.058 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 8.757393e-01 | 0.058 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 8.757393e-01 | 0.058 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 8.785411e-01 | 0.056 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 8.787933e-01 | 0.056 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 8.819093e-01 | 0.055 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 8.819093e-01 | 0.055 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 8.819093e-01 | 0.055 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 8.877734e-01 | 0.052 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 8.877734e-01 | 0.052 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 8.892561e-01 | 0.051 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 8.905788e-01 | 0.050 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 8.933466e-01 | 0.049 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 8.933466e-01 | 0.049 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 8.970941e-01 | 0.047 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 8.982112e-01 | 0.047 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 8.986433e-01 | 0.046 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 8.986433e-01 | 0.046 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 8.992932e-01 | 0.046 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.036773e-01 | 0.044 | 0 | 0 |
| Diseases associated with N-glycosylation of proteins | R-HSA-3781860 | 9.036773e-01 | 0.044 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.061571e-01 | 0.043 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.082822e-01 | 0.042 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 9.084616e-01 | 0.042 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 9.084616e-01 | 0.042 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 9.084616e-01 | 0.042 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.099091e-01 | 0.041 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 9.099091e-01 | 0.041 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.114248e-01 | 0.040 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 9.130085e-01 | 0.040 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.130085e-01 | 0.040 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.135201e-01 | 0.039 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.138490e-01 | 0.039 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 9.146060e-01 | 0.039 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 9.146060e-01 | 0.039 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 9.146060e-01 | 0.039 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 9.169951e-01 | 0.038 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 9.173298e-01 | 0.037 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 9.173298e-01 | 0.037 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 9.173298e-01 | 0.037 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.173298e-01 | 0.037 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 9.205306e-01 | 0.036 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 9.214367e-01 | 0.036 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 9.214367e-01 | 0.036 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.214367e-01 | 0.036 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.216334e-01 | 0.035 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.221089e-01 | 0.035 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 9.236422e-01 | 0.034 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 9.253398e-01 | 0.034 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 9.266486e-01 | 0.033 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.324848e-01 | 0.030 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 9.325746e-01 | 0.030 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 9.325746e-01 | 0.030 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.359250e-01 | 0.029 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 9.359250e-01 | 0.029 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 9.378797e-01 | 0.028 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 9.391091e-01 | 0.027 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.391091e-01 | 0.027 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 9.421352e-01 | 0.026 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.423534e-01 | 0.026 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 9.428084e-01 | 0.026 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 9.448896e-01 | 0.025 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 9.450110e-01 | 0.025 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 9.450110e-01 | 0.025 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.450110e-01 | 0.025 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 9.452112e-01 | 0.024 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 9.477441e-01 | 0.023 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.503415e-01 | 0.022 | 0 | 0 |
| Branched-chain amino acid catabolism | R-HSA-70895 | 9.503415e-01 | 0.022 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 9.513583e-01 | 0.022 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 9.525303e-01 | 0.021 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 9.551558e-01 | 0.020 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 9.575991e-01 | 0.019 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.591728e-01 | 0.018 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.634309e-01 | 0.016 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 9.634309e-01 | 0.016 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 9.649358e-01 | 0.016 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 9.649358e-01 | 0.016 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 9.652493e-01 | 0.015 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 9.652493e-01 | 0.015 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 9.669775e-01 | 0.015 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.670867e-01 | 0.015 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.670867e-01 | 0.015 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.678471e-01 | 0.014 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.686198e-01 | 0.014 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 9.686198e-01 | 0.014 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 9.686198e-01 | 0.014 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 9.686198e-01 | 0.014 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 9.686198e-01 | 0.014 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 9.686198e-01 | 0.014 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 9.687456e-01 | 0.014 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 9.687456e-01 | 0.014 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.698145e-01 | 0.013 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 9.730732e-01 | 0.012 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 9.730732e-01 | 0.012 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 9.745890e-01 | 0.011 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.757601e-01 | 0.011 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.768952e-01 | 0.010 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.780447e-01 | 0.010 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 9.786418e-01 | 0.009 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 9.791372e-01 | 0.009 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.793057e-01 | 0.009 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 9.816698e-01 | 0.008 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.820993e-01 | 0.008 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.820993e-01 | 0.008 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.838368e-01 | 0.007 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.846414e-01 | 0.007 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.854059e-01 | 0.006 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.854059e-01 | 0.006 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 9.868228e-01 | 0.006 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 9.874788e-01 | 0.005 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 9.874788e-01 | 0.005 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 9.881023e-01 | 0.005 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.894970e-01 | 0.005 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.900681e-01 | 0.004 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 9.920615e-01 | 0.003 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 9.920937e-01 | 0.003 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.924390e-01 | 0.003 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.924876e-01 | 0.003 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.935555e-01 | 0.003 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.938221e-01 | 0.003 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.955543e-01 | 0.002 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 9.955822e-01 | 0.002 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.957188e-01 | 0.002 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.957188e-01 | 0.002 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 9.961350e-01 | 0.002 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.961350e-01 | 0.002 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.961845e-01 | 0.002 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.963278e-01 | 0.002 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.964529e-01 | 0.002 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.968399e-01 | 0.001 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.970073e-01 | 0.001 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 9.972875e-01 | 0.001 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 9.975612e-01 | 0.001 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.979083e-01 | 0.001 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.980126e-01 | 0.001 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.984615e-01 | 0.001 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.986112e-01 | 0.001 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 9.986890e-01 | 0.001 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.987208e-01 | 0.001 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.992156e-01 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.993950e-01 | 0.000 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.994043e-01 | 0.000 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.994043e-01 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 9.994478e-01 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 9.994478e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.995283e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.996143e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 9.996336e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.996757e-01 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.997199e-01 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 9.997749e-01 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.998120e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.998400e-01 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 9.999084e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.999399e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.999712e-01 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.999765e-01 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 9.999931e-01 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 9.999942e-01 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.999949e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999996e-01 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 9.999998e-01 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |